Abbvie | Humira | Adalimumab | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 18,427 | 16,078 | 18,427 | 16,078 | 2,349 | 15 |
Abbvie | Androgel | Testosterone | Hormonal Disorders | USD | Millions | 577 | 675 | 577 | 675 | -98 | -15 |
Abbvie | Kaletra | Lopinavir/Ritonavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 423 | 549 | 423 | 549 | -126 | -23 |
Abbvie | Synagis | Palivizumab | Respiratory Disorders | USD | Millions | 738 | 730 | 738 | 730 | 8 | 1 |
Abbvie | Lupron | Leuprolide Acetate | Oncology | USD | Millions | 829 | 821 | 829 | 821 | 8 | 1 |
Abbvie | Synthroid | Levothyroxine Sodium | Hormonal Disorders | USD | Millions | 781 | 763 | 781 | 763 | 18 | 2 |
Abbvie | Sevoflurane | Sevoflurane | Anaesthetic | USD | Millions | 410 | 428 | 410 | 428 | -18 | -4 |
Abbvie | Creon | Pancrelipase | Rare Diseases | USD | Millions | 831 | 730 | 831 | 730 | 101 | 14 |
Abbvie | Duodopa | Carbidopa/Levodopa | Neurological/Mental Disorders | USD | Millions | 355 | 293 | 355 | 293 | 62 | 21 |
Abbvie | HCV | | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,274 | 1,522 | 1,274 | 1,522 | -248 | -16 |
Abbvie | Imbruvica | Ibrutinib | Oncology | USD | Millions | 2,573 | 1,832 | 2,573 | 1,832 | 741 | 40 |
Abbvie | Others | | | USD | Millions | 998 | 1,217 | 998 | 1,217 | -219 | -18 |
Abbvie | Total Sales | | | USD | Millions | 28,216 | 25,638 | 28,216 | 25,638 | 2,578 | 10 |
Abbott | Pediatric | | | USD | Millions | 3,889 | 3,883 | 3,889 | 3,883 | 6 | 0.2 |
Abbott | Adult | | | USD | Millions | 3,036 | 3,016 | 3,036 | 3,016 | 20 | 1 |
Abbott | Total Nutrition | | | USD | Millions | 6,925 | 6,899 | 6,925 | 6,899 | 26 | 0.4 |
Abbott | Core Laboratory | | | USD | Millions | 4,063 | 3,844 | 4,063 | 3,844 | 219 | 6 |
Abbott | Molecular | | | USD | Millions | 463 | 456 | 463 | 456 | 7 | 2 |
Abbott | Point of Care | | | USD | Millions | 550 | 513 | 550 | 513 | 37 | 7 |
Abbott | Rapid Diagnostics | | | USD | Millions | 540 | Not Available | 540 | Not Available | 540 | Not Available |
Abbott | Total Diagnostics | | | USD | Millions | 5,616 | 4,813 | 5,616 | 4,813 | 803 | 17 |
Abbott | Key Emerging Markets | | | USD | Millions | 3,307 | 2,912 | 3,307 | 2,912 | 395 | 14 |
Abbott | Others | | | USD | Millions | 980 | 947 | 980 | 947 | 33 | 3 |
Abbott | Total Established Pharmaceuticals | | | USD | Millions | 4,287 | 3,859 | 4,287 | 3,859 | 428 | 11 |
Abbott | Cardiovascular and Neuromodulation | | | USD | Millions | 8,911 | 2,896 | 8,911 | 2,896 | 6,015 | 208 |
Abbott | Other Sales | | | USD | Millions | 1,651 | 2,386 | 1,651 | 2,386 | -735 | -31 |
Abbott | Total Sales | | | USD | Millions | 27,390 | 20,853 | 27,390 | 20,853 | 6,537 | 31 |
Allergan | Botox | Onabotulinumtoxin A | Urology | USD | Millions | 3,169 | 2,786 | 3,169 | 2,786 | 383 | 14 |
Allergan | Restasis | Cyclosporine | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 1,474 | 1,488 | 1,474 | 1,488 | -14 | -1 |
Allergan | Fillers | | | USD | Millions | 1,042 | 867 | 1,042 | 867 | 175 | 20 |
Allergan | Lumigan/Ganfort | Bimatoprost | Ophthalmology | USD | Millions | 689 | 688 | 689 | 688 | 1 | 0.1 |
Allergan | Linzess/Constella | Linaclotide | Gastrointestinal Disorders | USD | Millions | 723 | 643 | 723 | 643 | 80 | 12 |
Allergan | Bystolic/Byvalson | Nebivolol | Cardiovascular Diseases | USD | Millions | 614 | 641 | 614 | 641 | -27 | -4 |
Allergan | Namenda XR | Memantine Hydrochloride | Alzheimer Disease | USD | Millions | 453 | 628 | 453 | 628 | -175 | -28 |
Allergan | Alphagan/Combigan | Brimonidine Tartrate/Timolol Maleate | Ophthalmology | USD | Millions | 552 | 546 | 552 | 546 | 6 | 1 |
Allergan | Eye Drops | | Ophthalmology | USD | Millions | 481 | 463 | 481 | 463 | 18 | 4 |
Allergan | Asacol/Delzicol | Mesalazine | Gastrointestinal Disorders | USD | Millions | 246 | 415 | 246 | 415 | -169 | -41 |
Allergan | Lo Loestrin | Norethindrone Acetate/Ethinyl estradiol | Sexual Health | USD | Millions | 459 | 404 | 459 | 404 | 56 | 14 |
Allergan | EstraceCream | Estradiol | Sexual Health | USD | Millions | 367 | 379 | 367 | 379 | -12 | -3 |
Allergan | Breast Implants | | | USD | Millions | 400 | 356 | 400 | 356 | 44 | 12 |
Allergan | Viibryd/Fetzima | Vilazodone | Neurological/Mental Disorders | USD | Millions | 336 | 342 | 336 | 342 | -6 | -2 |
Allergan | Minastrin24 | Ethinyl Estradiol, Norethindrone | Sexual Health | USD | Millions | 61 | 327 | 61 | 327 | -266 | -81 |
Allergan | Ozurdex | Dexamethasone | Ophthalmology | USD | Millions | 312 | 263 | 312 | 263 | 49 | 18 |
Allergan | Carafate /Sulcrate | Sucralfate | Gastrointestinal Disorders | USD | Millions | 239 | 231 | 239 | 231 | 8 | 3 |
Allergan | Aczone | Dapsone | Dermatology | USD | Millions | 167 | 217 | 167 | 217 | -50 | -23 |
Allergan | Zenpep | Pancrelipase | Gastrointestinal Disorders | USD | Millions | 212 | 201 | 212 | 201 | 11 | 6 |
Allergan | Canasa/Salofalk | Mesalazine | Gastrointestinal Disorders | USD | Millions | 181 | 196 | 181 | 196 | -15 | -8 |
Allergan | Saphris | Asenapine | Neurological/Mental Disorders | USD | Millions | 155 | 167 | 155 | 167 | -12 | -7 |
Allergan | Armour Thyroid | Thyroid Extract | Hypothyroidism | USD | Millions | 169 | 167 | 169 | 167 | 3 | 2 |
Allergan | Teflaro | Ceftaroline | Dermatology | USD | Millions | 122 | 134 | 122 | 134 | -12 | -9 |
Allergan | Rapaflo | Silodosin | Renal Disorders | USD | Millions | 115 | 122 | 115 | 122 | -7 | -6 |
Allergan | SkinMedica | | Dermatology | USD | Millions | 101 | 108 | 101 | 108 | -7 | -7 |
Allergan | Savella | Milnacipran HCl | Fibromyalgia | USD | Millions | 98 | 103 | 98 | 103 | -5 | -5 |
Allergan | Tazorac | Tazarotene | Dermatology | USD | Millions | 66 | 96 | 66 | 96 | -30 | -31 |
Allergan | Vraylar | Cariprazine | Neurological/Mental Disorders | USD | Millions | 289 | 94 | 289 | 94 | 195 | 206 |
Allergan | Viberzi | Eluxadoline | Gastrointestinal Disorders | USD | Millions | 157 | 93 | 157 | 93 | 64 | 68 |
Allergan | Latisse | Bimatoprost | Hypotrichosis of Eyelashes | USD | Millions | 65 | 86 | 65 | 86 | -21 | -25 |
Allergan | Lexapro | Escitalopram oxalate | Neurological/Mental Disorders | USD | Millions | 52 | 67 | 52 | 67 | -15 | -22 |
Allergan | Namzaric | Memantine and Donepezil Hydrochloride | Neurological/Mental Disorders | USD | Millions | 131 | 58 | 131 | 58 | 74 | 128 |
Allergan | Kybella/Belkyra | Deoxycholic Acid | Submental Fat | USD | Millions | 56 | 53 | 56 | 53 | 4 | 7 |
Allergan | Dalvance | Dalbavancin | Dermatology | USD | Millions | 56 | 39 | 56 | 39 | 17 | 42 |
Allergan | Avycaz | Ceftazidime and Avibactam | Gastrointestinal Disorders | USD | Millions | 61 | 36 | 61 | 36 | 25 | 69 |
Allergan | Liletta | Levonorgestrel | Sexual Health | USD | Millions | 38 | 23 | 38 | 23 | 15 | 63 |
Allergan | Enablex | Darifenacin | Renal Disorders | USD | Millions | 4 | 17 | 4 | 17 | -13 | -77 |
Allergan | Namenda IR | Memantine Hydrochloride | Alzheimer Disease | USD | Millions | 0.1 | 15 | 0.1 | 15 | -15 | -99 |
Allergan | Other Revenues | | | USD | Millions | 1,372 | 1,091 | 1,372 | 1,091 | 281 | 26 |
Allergan | Less product sold through our former ANDA Distribution business | | | USD | Millions | Not Available | -80 | Not Available | -80 | -80 | 100 |
Allergan | Total Net Revenues | | | USD | Millions | 15,941 | 14,571 | 15,941 | 14,571 | 1,370 | 9 |
Alexion | Soliris | Eculizumab | Blood Disorders | USD | Millions | 3,144 | 2,843 | 3,144 | 2,843 | 301 | 11 |
Alexion | Strensiq | Asfotase Alfa | Metabolic Disorders | USD | Millions | 340 | 210 | 340 | 210 | 130 | 62 |
Alexion | Kanuma | Sebelipase Alfa | Metabolic Disorders | USD | Millions | 66 | 29 | 66 | 29 | 37 | 126 |
Alexion | Others | | | USD | Millions | 2 | 2 | 2 | 2 | 0 | -20 |
Alexion | Total Net Product Sales | | | USD | Millions | 3,551 | 3,084 | 3,551 | 3,084 | 467 | 15 |
Amgen | Neulasta | Pegfilgrastim | Blood Disorders | USD | Millions | 4,534 | 4,648 | 4,534 | 4,648 | -114 | -2 |
Amgen | Neupogen | Filgrastim | Blood Disorders | USD | Millions | 549 | 765 | 549 | 765 | -216 | -28 |
Amgen | Enbrel | Etanercept | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 5,433 | 5,965 | 5,433 | 5,965 | -532 | -9 |
Amgen | Xgeva | Denosumab | Oncology | USD | Millions | 1,575 | 1,529 | 1,575 | 1,529 | 46 | 3 |
Amgen | Prolia | Denosumab | Bone and Joint Diseases | USD | Millions | 1,968 | 1,635 | 1,968 | 1,635 | 333 | 20 |
Amgen | Epogen | Epoetin Alfa | Blood Disorders | USD | Millions | 1,096 | 1,282 | 1,096 | 1,282 | -186 | -15 |
Amgen | Aranesp | Darbepoetin Alfa | Blood Disorders | USD | Millions | 2,053 | 2,093 | 2,053 | 2,093 | -40 | -2 |
Amgen | Sensipar/Mimpara | Cinacalcet | Hormonal Disorders | USD | Millions | 1,718 | 1,582 | 1,718 | 1,582 | 136 | 9 |
Amgen | Vectibix | Panitumumab | Oncology | USD | Millions | 642 | 611 | 642 | 611 | 31 | 5 |
Amgen | Nplate | Romiplostim | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 642 | 584 | 642 | 584 | 58 | 10 |
Amgen | Kyprolis | Carfilzomib | Oncology | USD | Millions | 835 | 692 | 835 | 692 | 143 | 21 |
Amgen | Blincyto | Blinatumomab | Oncology | USD | Millions | 175 | 115 | 175 | 115 | 60 | 52 |
Amgen | Repatha | Evolocumab | Cardiovascular Diseases | USD | Millions | 319 | 141 | 319 | 141 | 178 | 126 |
Amgen | Others | | | USD | Millions | 256 | 250 | 256 | 250 | 6 | 2 |
Amgen | Total Pharmaceuticals | | | USD | Millions | 21,795 | 21,892 | 21,795 | 21,892 | -97 | -0.4 |
Amgen | Other Revenues | | | USD | Millions | 1,054 | 1,099 | 1,054 | 1,099 | -45 | -4 |
Amgen | Total Revenues | | | USD | Millions | 22,849 | 22,991 | 22,849 | 22,991 | -142 | -1 |
AstraZeneca | Crestor | Rosuvastatin Calcium | Cardiovascular Diseases | USD | Millions | 2,365 | 3,401 | 2,365 | 3,401 | -1,036 | -30 |
AstraZeneca | Seloken/Toprol-XL | Metoprolol Hydrochloride | Cardiovascular Diseases | USD | Millions | 695 | 737 | 695 | 737 | -42 | -6 |
AstraZeneca | Onglyza/Kombiglyze XR/Komboglyze | Saxagliptin/Saxagliptin + Metoprolol Hydrochloride | Diabetes | USD | Millions | 611 | 720 | 611 | 720 | -109 | -15 |
AstraZeneca | Atacand | Candesartan | Cardiovascular Diseases | USD | Millions | 300 | 315 | 300 | 315 | -15 | -5 |
AstraZeneca | Brilinta/Brilique | Ticagrelor | Cardiovascular Diseases | USD | Millions | 1,079 | 839 | 1,079 | 839 | 240 | 29 |
AstraZeneca | Byetta | Exenatide | Diabetes | USD | Millions | 176 | 254 | 176 | 254 | -78 | -31 |
AstraZeneca | Bydureon | Exenatide | Diabetes | USD | Millions | 574 | 578 | 574 | 578 | -4 | -1 |
AstraZeneca | Farxiga/Forxiga | Dapagliflozin | Diabetes | USD | Millions | 1,074 | 835 | 1,074 | 835 | 239 | 29 |
AstraZeneca | Symlin | Pramlintide Acetate | Diabetes | USD | Millions | 48 | 0 | 48 | 0 | 48 | New Launch |
AstraZeneca | Qtern | Dapagliflozin/Saxagliptin | Diabetes | USD | Millions | 5 | 0 | 5 | 0 | 5 | New Launch |
AstraZeneca | Other Products | | | USD | Millions | 339 | 437 | 339 | 437 | -98 | -22 |
AstraZeneca | Total Cardiovascular and Metabolic Diseases | | | USD | Millions | 7,266 | 8,116 | 7,266 | 8,116 | -850 | -10 |
AstraZeneca | Zoladex | Goserelin Acetate | Oncology | USD | Millions | 735 | 816 | 735 | 816 | -81 | -10 |
AstraZeneca | Faslodex | Fulvestrant | Oncology | USD | Millions | 941 | 830 | 941 | 830 | 111 | 13 |
AstraZeneca | Iressa | Gefitinib | Oncology | USD | Millions | 528 | 513 | 528 | 513 | 15 | 3 |
AstraZeneca | Arimidex | Anastrozole | Oncology | USD | Millions | 217 | 232 | 217 | 232 | -15 | -6 |
AstraZeneca | Casodex | Bicalutamide | Oncology | USD | Millions | 215 | 247 | 215 | 247 | -32 | -13 |
AstraZeneca | Lynparza | Olaparib | Oncology | USD | Millions | 297 | 218 | 297 | 218 | 79 | 36 |
AstraZeneca | Tagrisso | Osimertinib | Oncology | USD | Millions | 955 | 423 | 955 | 423 | 532 | 126 |
AstraZeneca | Imfinzi | Durvalumab | Oncology | USD | Millions | 19 | 0 | 19 | 0 | 19 | New Launch |
AstraZeneca | Calquence | Acalabrutinib | Oncology | USD | Millions | 3 | 0 | 3 | 0 | 3 | New Launch |
AstraZeneca | Other Products | | | USD | Millions | 114 | 104 | 114 | 104 | 10 | 10 |
AstraZeneca | Total Oncology | | | USD | Millions | 4,024 | 3,383 | 4,024 | 3,383 | 641 | 19 |
AstraZeneca | Symbicort | Budesonide and Formoterol | Respiratory Disorders | USD | Millions | 2,803 | 2,989 | 2,803 | 2,989 | -186 | -6 |
AstraZeneca | Pulmicort | Budesonide | Respiratory Disorders | USD | Millions | 1,176 | 1,061 | 1,176 | 1,061 | 115 | 11 |
AstraZeneca | Tudorza/Eklira | Aclidinium Bromide | Respiratory Disorders | USD | Millions | 150 | 170 | 150 | 170 | -20 | -12 |
AstraZeneca | Daliresp/Daxas | Roflumilast | Respiratory Disorders | USD | Millions | 198 | 154 | 198 | 154 | 44 | 29 |
AstraZeneca | Duaklir | Aclidinium Bromide/Formoterol Fumarate | Respiratory Disorders | USD | Millions | 79 | 63 | 79 | 63 | 16 | 25 |
AstraZeneca | Bevespi | Glycopyrrolate/Formoterol Fumarate | Respiratory Disorders | USD | Millions | 16 | 0 | 16 | 0 | 16 | New Launch |
AstraZeneca | Other Products | | | USD | Millions | 284 | 316 | 284 | 316 | -32 | -10 |
AstraZeneca | Total Respiratory, Inflammation and Autoimmunity | | | USD | Millions | 4,706 | 4,753 | 4,706 | 4,753 | -47 | -1 |
AstraZeneca | Synagis | Palivizumab | Respiratory Disorders | USD | Millions | 687 | 677 | 687 | 677 | 10 | 1 |
AstraZeneca | FluMist/Fluenz | Influenza Vaccine Live, Intranasal | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 78 | 104 | 78 | 104 | -26 | -25 |
AstraZeneca | Movantik/Moventig | Naloxegol | Gastrointestinal Disorders | USD | Millions | 122 | 91 | 122 | 91 | 31 | 34 |
AstraZeneca | Seroquel XR | Quetiapine Fumarate | Neurological/Mental Disorders | USD | Millions | 332 | 735 | 332 | 735 | -403 | -55 |
AstraZeneca | Nexium | Esomeprazole Magnesium | Gastrointestinal Disorders | USD | Millions | 1,952 | 2,032 | 1,952 | 2,032 | -80 | -4 |
AstraZeneca | Losec/Prilosec | Omeprazole | Gastrointestinal Disorders | USD | Millions | 271 | 276 | 271 | 276 | -5 | -2 |
AstraZeneca | Other Products | | | USD | Millions | 714 | 1,152 | 714 | 1,152 | -438 | -38 |
AstraZeneca | Total Other | | | USD | Millions | 4,156 | 5,067 | 4,156 | 5,067 | -911 | -18 |
AstraZeneca | Total Product Sales | | | USD | Millions | 20,152 | 21,319 | 20,152 | 21,319 | -1,167 | -5 |
AstraZeneca | Total Externalisation Revenues | | | USD | Millions | 2,313 | 1,683 | 2,313 | 1,683 | 630 | 37 |
AstraZeneca | Total Revenues | | | USD | Millions | 22,465 | 23,002 | 22,465 | 23,002 | -537 | -2 |
Astellas Pharma | Symbicort | Budesonide and Formoterol | Respiratory Disorders | YEN | Millions | 39,700 | 38,400 | 381 | 369 | 12 | 3 |
Astellas Pharma | Xtandi | Enzalutamide | Oncology | YEN | Millions | 269,240 | 253,200 | 2,585 | 2,431 | 154 | 6 |
Astellas Pharma | Lipitor | Atorvastatin Calcium | Cardiovascular Diseases | YEN | Millions | 20,600 | 24,600 | 198 | 236 | -38 | -16 |
Astellas Pharma | Prograf | Tacrolimus | Immunology (Organ Transplant, Arthritis etc.) | YEN | Millions | 153,900 | 188,300 | 1,477 | 1,808 | -330 | -18 |
Astellas Pharma | Vesicare | Solifenacin Succinate | Renal Disorders | YEN | Millions | 98,290 | 120,100 | 944 | 1,153 | -209 | -18 |
Astellas Pharma | Ambisome | Amphotericin B | Infectious Diseases (HIV, Hepatitis etc.) | YEN | Millions | 10,810 | 10,500 | 104 | 101 | 3 | 3 |
Astellas Pharma | Micardis | Telmisartan | Cardiovascular Diseases | YEN | Millions | 60,200 | 93,700 | 578 | 900 | -322 | -36 |
Astellas Pharma | Betanis/Myrbetriq/Beiga | Mirabegron | Renal Disorders | YEN | Millions | 111,480 | 93,200 | 1,070 | 895 | 175 | 20 |
Astellas Pharma | Seroquel | Quetiapine Fumarate | Neurological/Mental Disorders | YEN | Millions | 6,500 | 8,000 | 62 | 77 | -14 | -19 |
Astellas Pharma | Adenoscan/Lexiscan | Adenosine/Regadenoson | Diagnostic | YEN | Millions | 69,760 | 69,900 | 670 | 671 | -1 | -0.2 |
Astellas Pharma | Myslee | Zolpidem | Neurological/Mental Disorders | YEN | Millions | 13,600 | 15,300 | 131 | 147 | -16 | -11 |
Astellas Pharma | Celecox | Celecoxib | Anti-inflammatory | YEN | Millions | 48,400 | 47,600 | 465 | 457 | 8 | 2 |
Astellas Pharma | Harnal/Omnic | Tamsulosin | Renal Disorders | YEN | Millions | 26,500 | 47,300 | 254 | 454 | -200 | -44 |
Astellas Pharma | Funguard/Mycamine | Micafungin Sodium | Anti-fungal | YEN | Millions | 34,070 | 40,300 | 327 | 387 | -60 | -15 |
Astellas Pharma | Tarceva | Erlotinib | Oncology | YEN | Millions | 30,000 | 36,800 | 288 | 353 | -65 | -18 |
Astellas Pharma | Vaccines | Vaccines | Vaccine | YEN | Millions | 29,200 | 34,100 | 280 | 327 | -47 | -14 |
Astellas Pharma | Eligard | Leuprorelin | Oncology | YEN | Millions | 16,560 | 16,000 | 159 | 154 | 5 | 4 |
Astellas Pharma | Protopic | Tacrolimus | Immunology (Organ Transplant, Arthritis etc.) | YEN | Millions | 0 | 3,500 | 0 | 34 | -34 | -100 |
Astellas Pharma | Bonoteo | Minodronic Acid | Bone and Joint Diseases | YEN | Millions | 13,500 | 13,900 | 130 | 133 | -4 | -3 |
Astellas Pharma | Gaster | Famotidine | Gastrointestinal Disorders | YEN | Millions | 2,200 | 11,400 | 21 | 109 | -88 | -81 |
Astellas Pharma | Geninax | Garenoxacin | Anti-bacterial | YEN | Millions | 9,400 | 10,100 | 90 | 97 | -7 | -7 |
Astellas Pharma | Suglat | Ipragliflozin | Diabetes | YEN | Millions | 11,800 | 9,100 | 113 | 87 | 26 | 30 |
Astellas Pharma | Cimzia | Certolizumab Pegol | Anti-inflammatory | YEN | Millions | 8,800 | 7,600 | 84 | 73 | 12 | 16 |
Astellas Pharma | Argamate | Calcium Polystyrene Sulphonate | Hyperkalemia | YEN | Millions | 5,800 | 5,900 | 56 | 57 | -1 | -2 |
Astellas Pharma | Cresemba | Isavuconazonium Sulfate | Anti-fungal | YEN | Millions | 8,070 | 5,000 | 77 | 48 | 29 | 61 |
Astellas Pharma | Gonax | Degarelix Acetate | Oncology | YEN | Millions | 4,700 | 4,300 | 45 | 41 | 4 | 9 |
Astellas Pharma | Dificlir | Fidaxomicin | Infectious Diseases (HIV, Hepatitis etc.) | YEN | Millions | 0 | 2,200 | 0 | 21 | -21 | -100 |
Astellas Pharma | Repatha | Evolocumab | Cardiovascular Diseases | YEN | Millions | 1,100 | 0 | 11 | 0 | 11 | New Launch |
Astellas Pharma | Linzess | Linaclotide | Gastrointestinal Disorders | YEN | Millions | 900 | 0 | 9 | 0 | 9 | New Launch |
Astellas Pharma | Qutenza | Capasaicin | Neuropathic Pain | YEN | Millions | 0 | 2,000 | 0 | 19 | -19 | -100 |
Astellas Pharma | Kiklin | Bixalomer | Renal Disorders | YEN | Millions | 0 | 1,600 | 0 | 15 | -15 | -100 |
Astellas Pharma | Product Sales | | | YEN | Millions | 1,105,080 | 1,213,900 | 10,609 | 11,653 | -1,045 | -9 |
Astellas Pharma | Others | | | YEN | Millions | 46,000 | 98,700 | 442 | 948 | -506 | -53 |
Astellas Pharma | Total Sales | | | YEN | Millions | 1,151,170 | 1,312,600 | 11,051 | 12,601 | -1,550 | -12 |
Bayer | Xarelto | Rivaroxaban | Cardiovascular Diseases | EURO | Millions | 3,298 | 2,928 | 4,090 | 3,631 | 459 | 13 |
Bayer | Eylea | Aflibercept | Ophthalmology | EURO | Millions | 1,880 | 1,625 | 2,331 | 2,015 | 316 | 16 |
Bayer | Xofigo | Radium Ra 223 Dichloride | Oncology | EURO | Millions | 408 | 331 | 506 | 410 | 95 | 23 |
Bayer | Stivarga | Regorafenib | Oncology | EURO | Millions | 315 | 275 | 391 | 341 | 50 | 15 |
Bayer | Adempas | Riociguat | Cardiovascular Diseases | EURO | Millions | 295 | 254 | 366 | 315 | 51 | 16 |
Bayer | Subtotal Key growth products | | | EURO | Millions | 6,196 | 5,413 | 7,683 | 6,712 | 971 | 14 |
Bayer | Mirena product family | Levonorgestrel | Sexual Health | EURO | Millions | 1,126 | 1,043 | 1,396 | 1,293 | 103 | 8 |
Bayer | Kogenate | Antihemophilic Factor (Recombinant) | Rare Diseases | EURO | Millions | 967 | 1,166 | 1,199 | 1,446 | -247 | -17 |
Bayer | Nexavar | Sorafenib | Oncology | EURO | Millions | 834 | 870 | 1,034 | 1,079 | -45 | -4 |
Bayer | Betaferon/Betaseron | Interferon Beta-1b | Neurological/Mental Disorders | EURO | Millions | 651 | 734 | 807 | 910 | -103 | -11 |
Bayer | Adalat | Nifedipine | Cardiovascular Diseases | EURO | Millions | 648 | 624 | 804 | 774 | 30 | 4 |
Bayer | YAZ/Yasim/Yasminelle | Drospirenone and Ethinyl Estradiol | Sexual Health | EURO | Millions | 648 | 678 | 804 | 841 | -37 | -4 |
Bayer | Aspirin Cardio | Acetylsalicylic Acid | Cardiovascular Diseases | EURO | Millions | 581 | 538 | 720 | 667 | 53 | 8 |
Bayer | Glucobay | Acarbose | Diabetes | EURO | Millions | 563 | 515 | 698 | 639 | 60 | 9 |
Bayer | Gadavist/Gadovist | Ezetimibe | Cardiovascular Diseases | EURO | Millions | 365 | 346 | 453 | 429 | 24 | 5 |
Bayer | Avalox/Avelox | Moxifloxacin Hydrochloride | Anti-bacterial | EURO | Millions | 333 | 353 | 413 | 438 | -25 | -6 |
Bayer | Total Best-selling products | | | EURO | Millions | 12,912 | 12,280 | 16,011 | 15,227 | 784 | 5 |
Bayer | Total Pharmaceuticals | | | EURO | Millions | 16,847 | 16,420 | 20,890 | 20,361 | 529 | 3 |
Bayer | Consumer Health | | | EURO | Millions | 5,862 | 6,037 | 7,269 | 7,486 | -217 | -3 |
Bayer | Crop Science | | | EURO | Millions | 9,577 | 9,915 | 11,875 | 12,295 | -419 | -3 |
Bayer | Animal Health | | | EURO | Millions | 1,571 | 1,523 | 1,948 | 1,889 | 60 | 3 |
Bayer | Total Life Science (Incl. Reconciliation) | | | EURO | Millions | 35,015 | 34,943 | 43,419 | 43,329 | 89 | 0.2 |
Bayer | Covestro | | | EURO | Millions | 10,556 | 11,826 | 13,089 | 14,664 | -1,575 | -11 |
Bayer | Total Group Sales | | | EURO | Millions | 45,571 | 46,769 | 56,508 | 57,994 | -1,486 | -3 |
Baxter | Renal Care | | | USD | Millions | 3,480 | 3,421 | 3,480 | 3,421 | 59 | 2 |
Baxter | Acute Therapies | | | USD | Millions | 456 | 429 | 456 | 429 | 27 | 6 |
Baxter | Medication Delivery | | | USD | Millions | 2,698 | 2,596 | 2,698 | 2,596 | 102 | 4 |
Baxter | Pharmaceuticals | | | USD | Millions | 1,883 | 1,722 | 1,883 | 1,722 | 161 | 9 |
Baxter | Nutrition | | | USD | Millions | 882 | 858 | 882 | 858 | 24 | 3 |
Baxter | Advanced Surgery | | | USD | Millions | 707 | 690 | 707 | 690 | 17 | 2 |
Baxter | Others | | | USD | Millions | 455 | 447 | 455 | 447 | 8 | 2 |
Baxter | Total Revenues | | | USD | Millions | 10,561 | 10,163 | 10,561 | 10,163 | 398 | 4 |
Biogen | Tecfidera | Dimethyl Fumarate | Neurological/Mental Disorders | USD | Millions | 4,214 | 3,968 | 4,214 | 3,968 | 246 | 6 |
Biogen | Avonex | Interferon Beta-1a | Neurological/Mental Disorders | USD | Millions | 2,152 | 2,314 | 2,152 | 2,314 | -162 | -7 |
Biogen | Plegridy | Peginterferon Beta-1a | Neurological/Mental Disorders | USD | Millions | 494 | 482 | 494 | 482 | 13 | 3 |
Biogen | Tysabri | Natalizumab | Neurological/Mental Disorders | USD | Millions | 1,973 | 1,964 | 1,973 | 1,964 | 9 | 0.5 |
Biogen | Fampyra | Fampridine | Neurological/Mental Disorders | USD | Millions | 92 | 85 | 92 | 85 | 7 | 8 |
Biogen | Zinbryta | Daclizumab | Neurological/Mental Disorders | USD | Millions | 53 | 8 | 53 | 8 | 45 | 576 |
Biogen | Total Multiple Sclerosis | | | USD | Millions | 8,977 | 8,820 | 8,977 | 8,820 | 157 | 2 |
Biogen | Eloctate | Antihemophilic Factor (Recombinant), Fc Fusion Protein | Blood Disorders | USD | Millions | 48 | 513 | 48 | 513 | -465 | -91 |
Biogen | Alprolix | Coagulation Factor IX (Recombinant), Fc Fusion Protein | Blood Disorders | USD | Millions | 26 | 334 | 26 | 334 | -308 | -92 |
Biogen | Hemophilia | | | USD | Millions | 74 | 847 | 74 | 847 | -773 | -91 |
Biogen | Spinraza | Nusinersen | Spinal Muscular Atrophy | USD | Millions | 884 | 5 | 884 | 5 | 879 | 19,111 |
Biogen | Spinal Muscular Atrophy | | | USD | Millions | 884 | 5 | 884 | 5 | 879 | 19,111 |
Biogen | Benepali | Etanercept | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 371 | 101 | 371 | 101 | 270 | 269 |
Biogen | Flixabi | Infliximab | Rheumatoid Arthritis | USD | Millions | 9 | 0.1 | 9 | 0.1 | 9 | 8,900 |
Biogen | Fumaderm | Dimethyl Fumarate | Anti-fungal | USD | Millions | 40 | 46 | 40 | 46 | -6 | -14 |
Biogen | Other Product Revenues | | | USD | Millions | 419 | 147 | 419 | 147 | 272 | 185 |
Biogen | Total Product Revenues | | | USD | Millions | 10,355 | 9,818 | 10,355 | 9,818 | 536 | 5 |
Biogen | Anti-CD20 Revenues | | | USD | Millions | 1,559 | 1,315 | 1,559 | 1,315 | 244 | 19 |
Biogen | Other Revenues | | | USD | Millions | 360 | 316 | 360 | 316 | 44 | 14 |
Biogen | Total Sales | | | USD | Millions | 12,274 | 11,450 | 12,274 | 11,450 | 824 | 7 |
Biomarin | Aldurazyme | Laronidase | Rare Diseases | USD | Millions | 90 | 94 | 90 | 94 | -4 | -4 |
Biomarin | Brineura | Cerliponase Alfa | Rare Diseases | USD | Millions | 9 | 0 | 9 | 0 | 9 | New Launch |
Biomarin | Firdapse | Amifampridine | Rare Diseases | USD | Millions | 19 | 18 | 19 | 18 | 1 | 4 |
Biomarin | Kuvan | Sapropterin Dihydrochloride | Hyperphenylalaninemia | USD | Millions | 408 | 348 | 408 | 348 | 60 | 17 |
Biomarin | Naglazyme | Galsulfase | Rare Diseases | USD | Millions | 332 | 297 | 332 | 297 | 36 | 12 |
Biomarin | Vimizim | Elosulfase Alfa | Rare Diseases | USD | Millions | 413 | 354 | 413 | 354 | 59 | 17 |
Biomarin | Net Product Revenues | | | USD | Millions | 1,270 | 1,110 | 1,270 | 1,110 | 160 | 14 |
Biomarin | Royalty and Other Revenues | | | USD | Millions | 43 | 7 | 43 | 7 | 37 | 565 |
Biomarin | Total Revenues | | | USD | Millions | 1,314 | 1,117 | 1,314 | 1,117 | 197 | 18 |
Bristol Myers Squibb | Baraclude | Entecavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,052 | 1,192 | 1,052 | 1,192 | -140 | -12 |
Bristol Myers Squibb | Hepatits C Franchise | Daclatasvir and Asunaprevir | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 406 | 1,578 | 406 | 1,578 | -1,172 | -74 |
Bristol Myers Squibb | Reyataz | Atazanavir Sulphate | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 698 | 912 | 698 | 912 | -214 | -23 |
Bristol Myers Squibb | Sustiva | Efavirenz | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 729 | 1,065 | 729 | 1,065 | -336 | -32 |
Bristol Myers Squibb | Total Virology | | | USD | Millions | 2,885 | 4,747 | 2,885 | 4,747 | -1,862 | -39 |
Bristol Myers Squibb | Empliciti | Elotuzumab | Oncology | USD | Millions | 231 | 150 | 231 | 150 | 81 | 54 |
Bristol Myers Squibb | Opdivo | Nivolumab | Oncology | USD | Millions | 4,948 | 3,774 | 4,948 | 3,774 | 1,174 | 31 |
Bristol Myers Squibb | Sprycel | Dasatinib | Oncology | USD | Millions | 2,005 | 1,824 | 2,005 | 1,824 | 181 | 10 |
Bristol Myers Squibb | Yervoy | Ipilimumab | Oncology | USD | Millions | 1,244 | 1,053 | 1,244 | 1,053 | 191 | 18 |
Bristol Myers Squibb | Total Oncology | | | USD | Millions | 8,428 | 6,801 | 8,428 | 6,801 | 1,627 | 24 |
Bristol Myers Squibb | Orencia | Abatacept | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 2,479 | 2,265 | 2,479 | 2,265 | 214 | 9 |
Bristol Myers Squibb | Total Immunoscience | | | USD | Millions | 2,479 | 2,265 | 2,479 | 2,265 | 214 | 9 |
Bristol Myers Squibb | Eliquis | Apixaban | Cardiovascular Diseases | USD | Millions | 4,872 | 3,343 | 4,872 | 3,343 | 1,529 | 46 |
Bristol Myers Squibb | Total Cardiovascular | | | USD | Millions | 4,872 | 3,343 | 4,872 | 3,343 | 1,529 | 46 |
Bristol Myers Squibb | Total Other Mature Products | | | USD | Millions | 2,112 | 2,271 | 2,112 | 2,271 | -159 | -7 |
Bristol Myers Squibb | Total Pharmaceuticals | | | USD | Millions | 20,776 | 19,427 | 20,776 | 19,427 | 1,349 | 7 |
Celgene | Revlimid | Lenalidomide | Oncology | USD | Millions | 8,187 | 6,974 | 8,187 | 6,974 | 1,213 | 17 |
Celgene | Abraxane | Paclitaxel Protein Bound | Oncology | USD | Millions | 992 | 973 | 992 | 973 | 19 | 2 |
Celgene | Pomalyst/Imnovid | Pomalidomide | Oncology | USD | Millions | 1,614 | 1,311 | 1,614 | 1,311 | 303 | 23 |
Celgene | Otezla | Apremilast | Dermatology | USD | Millions | 1,279 | 1,017 | 1,279 | 1,017 | 262 | 26 |
Celgene | Vidaza | Azacitidine | Oncology | USD | Millions | 628 | 608 | 628 | 608 | 20 | 3 |
Celgene | Azacitidine for Injection | Azacitidine | Oncology | USD | Millions | 36 | 66 | 36 | 66 | -30 | -45 |
Celgene | Thalomid | Thalidomide | Oncology | USD | Millions | 132 | 152 | 132 | 152 | -20 | -13 |
Celgene | Idhifa | Enasidenib | Oncology | USD | Millions | 20 | 0 | 20 | 0 | 20 | New Launch |
Celgene | Istodax | Romidepsin | Oncology | USD | Millions | 76 | 80 | 76 | 80 | -4 | -5 |
Celgene | Others | | | USD | Millions | 9 | 4 | 9 | 4 | 5 | 109 |
Celgene | Total Net Product Sales | | | USD | Millions | 12,973 | 11,185 | 12,973 | 11,185 | 1,788 | 16 |
Celgene | Other Revenues | | | USD | Millions | 30 | 45 | 30 | 45 | -15 | -33 |
Celgene | Total Revenues | | | USD | Millions | 13,003 | 11,229 | 13,003 | 11,229 | 1,774 | 16 |
Chugai Pharmaceuticals | Oncology | | | YEN | Millions | 225,900 | 220,300 | 2,169 | 2,115 | 54 | 3 |
Chugai Pharmaceuticals | Bone and Joint Diseases | | | YEN | Millions | 93,300 | 86,100 | 896 | 827 | 69 | 8 |
Chugai Pharmaceuticals | Renal Diseases | | | YEN | Millions | 39,300 | 41,100 | 377 | 395 | -17 | -4 |
Chugai Pharmaceuticals | Others | | | YEN | Millions | 29,900 | 32,200 | 287 | 309 | -22 | -7 |
Chugai Pharmaceuticals | Tamiflu Sales | Oseltamivir Phosphate | Anti-viral | YEN | Millions | 16,900 | 13,500 | 162 | 130 | 33 | 25 |
Chugai Pharmaceuticals | Ordinary use | | | YEN | Millions | 11,900 | 12,000 | 114 | 115 | -1 | -1 |
Chugai Pharmaceuticals | Government stockpiles | | | YEN | Millions | 5,000 | 1,500 | 48 | 14 | 34 | 233 |
Chugai Pharmaceuticals | Overseas | | | YEN | Millions | 94,000 | 79,500 | 902 | 763 | 139 | 18 |
Chugai Pharmaceuticals | Domestic sales (excluding Tamiflu) | | | YEN | Millions | 388,400 | 379,700 | 3,729 | 3,645 | 84 | 2 |
Chugai Pharmaceuticals | Total Sales | | | YEN | Millions | 499,300 | 472,700 | 4,793 | 4,538 | 255 | 6 |
Chugai Pharmaceuticals | Royalties and Other Operating Income | | | YEN | Millions | 34,900 | 19,100 | 335 | 183 | 152 | 83 |
Chugai Pharmaceuticals | Total Revenues | | | YEN | Millions | 534,200 | 491,800 | 5,128 | 4,721 | 407 | 9 |
Daiichi Sankyo | Nexium | Esomeprazole | Gastrointestinal Disorders | YEN | Millions | 87,800 | 86,600 | 843 | 831 | 12 | 1 |
Daiichi Sankyo | Memary | Memantine | Alzheimer Disease | YEN | Millions | 46,000 | 48,600 | 442 | 467 | -25 | -5 |
Daiichi Sankyo | Olmetec | Olmesartan Medoxomil | Cardiovascular Diseases | YEN | Millions | 67,500 | 55,800 | 648 | 536 | 112 | 21 |
Daiichi Sankyo | Lixiana | Edoxaban | Blood Disorders | YEN | Millions | 28,970 | 64,290 | 278 | 617 | -339 | -55 |
Daiichi Sankyo | Loxonin | Loxoprofen | Anti-inflammatory | YEN | Millions | 39,200 | 37,100 | 376 | 356 | 20 | 6 |
Daiichi Sankyo | Tenelia | Teneligliptin | Diabetes | YEN | Millions | 24,300 | 25,400 | 233 | 244 | -11 | -4 |
Daiichi Sankyo | Pralia | Denosumab | Bone and Joint Diseases | YEN | Millions | 16,700 | 22,000 | 160 | 211 | -51 | -24 |
Daiichi Sankyo | Rezaltas | Olmesartan Medoxomil/Azelnidipine | Cardiovascular Diseases | YEN | Millions | 17,700 | 17,000 | 170 | 163 | 7 | 4 |
Daiichi Sankyo | Ranmark | Denosumab | Bone and Joint Diseases | YEN | Millions | 13,600 | 15,000 | 131 | 144 | -13 | -9 |
Daiichi Sankyo | Efient | Prasugrel | Blood Disorders | YEN | Millions | 38,568 | 35,506 | 370 | 341 | 29 | 9 |
Daiichi Sankyo | Inavir | Laninamivir | Anti-influenza | YEN | Millions | 19,400 | 20,900 | 186 | 201 | -14 | -7 |
Daiichi Sankyo | Cravit | Levofloxacin | Anti-bacterial | YEN | Millions | 15,800 | 13,200 | 152 | 127 | 25 | 20 |
Daiichi Sankyo | Urief | Silodosin | Urology | YEN | Millions | 11,700 | 11,200 | 112 | 108 | 5 | 4 |
Daiichi Sankyo | Omnipaque | Iohexol | Contrast Medium | YEN | Millions | 14,700 | 14,100 | 141 | 135 | 6 | 4 |
Daiichi Sankyo | Mevalotin | Pravastatin | Cardiovascular Diseases | YEN | Millions | 11,000 | 9,200 | 106 | 88 | 17 | 20 |
Daiichi Sankyo | Welchol | Colesevelam | Blood Disorders | YEN | Millions | 41,870 | 40,280 | 402 | 387 | 15 | 4 |
Daiichi Sankyo | Savaysa | Edoxaban | Blood Disorders | YEN | Millions | 1,484 | 1,908 | 14 | 18 | -4 | -22 |
Daiichi Sankyo | Movantik | Naloxegol | Opioid-induced Constipation | YEN | Millions | 3,498 | 4,664 | 34 | 45 | -11 | -25 |
Daiichi Sankyo | Venofer | Iron Sucrose | Blood Disorders | YEN | Millions | 27,348 | 29,468 | 263 | 283 | -20 | -7 |
Daiichi Sankyo | Injectafer | Ferric Carboxymaltose | Blood Disorders | YEN | Millions | 22,260 | 30,316 | 214 | 291 | -77 | -27 |
Daiichi Sankyo | Total Revenues | | | YEN | Millions | 549,398 | 582,532 | 5,274 | 5,592 | -318 | -6 |
Dainippon Sumitomo | Aimix | Amlodipine, Irbesartan | Cardiovascular Diseases | YEN | Millions | 19,300 | 17,300 | 185 | 166 | 19 | 12 |
Dainippon Sumitomo | Trerief/Excegran | Zonisamide | Neurological/Mental Disorders | YEN | Millions | 16,800 | 15,600 | 161 | 150 | 12 | 8 |
Dainippon Sumitomo | Lonasen | Blonanserin | Neurological/Mental Disorders | YEN | Millions | 13,400 | 13,600 | 129 | 131 | -2 | -1 |
Dainippon Sumitomo | Metgluco | Biguanide | Diabetes | YEN | Millions | 11,400 | 11,600 | 109 | 111 | -2 | -2 |
Dainippon Sumitomo | Replagal | Agalsidase Alfa | Renal Disorders | YEN | Millions | 11,900 | 10,900 | 114 | 105 | 10 | 9 |
Dainippon Sumitomo | Trulicity | Dulaglutide | Diabetes | YEN | Millions | 15,200 | 5,000 | 146 | 48 | 98 | 204 |
Dainippon Sumitomo | Avapro | Irbesartan | Cardiovascular Diseases | YEN | Millions | 10,200 | 10,800 | 98 | 104 | -6 | -6 |
Dainippon Sumitomo | Surepost | Repaglinide | Diabetes | YEN | Millions | 5,100 | 4,400 | 49 | 42 | 7 | 16 |
Dainippon Sumitomo | Ambisome | Amphotericin B | Anti-fungal | YEN | Millions | 4,500 | 4,500 | 43 | 43 | 0 | 0.0 |
Dainippon Sumitomo | Amlodin | Amlodipine | Cardiovascular Diseases | YEN | Millions | 12,200 | 13,800 | 117 | 132 | -15 | -12 |
Dainippon Sumitomo | Prorenal | Limaprost Alfadex | Neurological/Mental Disorders | YEN | Millions | 5,900 | 7,000 | 57 | 67 | -11 | -16 |
Dainippon Sumitomo | Gasmotin | Mosapride Citrate | Gastrointestinal Disorders | YEN | Millions | 5,400 | 6,500 | 52 | 62 | -11 | -17 |
Dainippon Sumitomo | Meropen | Meropenem Hydrate | Anti-bacterial | YEN | Millions | 30,200 | 26,900 | 290 | 258 | 32 | 12 |
Dainippon Sumitomo | Latuda | Lurasidone | Neurological/Mental Disorders | YEN | Millions | 349,000 | 255,770 | 3,350 | 2,455 | 895 | 36 |
Dainippon Sumitomo | Brovana | Arformoterol | Respiratory Disorders | YEN | Millions | 66,000 | 64,560 | 634 | 620 | 14 | 2 |
Dainippon Sumitomo | Aptiom | Eslicarbazepine | Neurological/Mental Disorders | YEN | Millions | 29,000 | 20,760 | 278 | 199 | 79 | 40 |
Dainippon Sumitomo | Ciclesonide | Ciclesonide | Respiratory Disorders | YEN | Millions | 5,000 | 10,590 | 48 | 102 | -54 | -53 |
Dainippon Sumitomo | Xopenex | Levalbuterol | Respiratory Disorders | YEN | Millions | 7,000 | 10,590 | 67 | 102 | -34 | -34 |
Dainippon Sumitomo | New products for COPD | | | YEN | Millions | 920 | 0 | 9 | 0 | 9 | Not Available |
Dainippon Sumitomo | Total Sales | | | YEN | Millions | 618,000 | 510,000 | 5,933 | 4,896 | 1,037 | 21 |
Eisai Co. Ltd. | Humira | Adalimumab | Immunology (Organ Transplant, Arthritis etc.) | YEN | Millions | 54,100 | 46,000 | 519 | 442 | 78 | 18 |
Eisai Co. Ltd. | Lyrica | Pregabalin | Neurological/Mental Disorders | YEN | Millions | 26,400 | 24,300 | 253 | 233 | 20 | 9 |
Eisai Co. Ltd. | Aricept | Donepezil | Neurological/Mental Disorders | YEN | Millions | 44,660 | 46,700 | 429 | 448 | -20 | -4 |
Eisai Co. Ltd. | Pariet | Rabeprazole | Gastrointestinal Disorders | YEN | Millions | 26,700 | 29,700 | 256 | 285 | -29 | -10 |
Eisai Co. Ltd. | Methycobal | Methylcobalamin | Neurological/Mental Disorders | YEN | Millions | 40,000 | 38,800 | 384 | 372 | 12 | 3 |
Eisai Co. Ltd. | Lunesta | Eszopiclone | Neurological/Mental Disorders | YEN | Millions | 9,900 | 7,500 | 95 | 72 | 23 | 32 |
Eisai Co. Ltd. | Halaven | Eribulin | Oncology | YEN | Millions | 39,600 | 38,600 | 380 | 371 | 10 | 3 |
Eisai Co. Ltd. | Treakisym | Bendamustine | Oncology | YEN | Millions | 6,500 | 4,200 | 62 | 40 | 22 | 55 |
Eisai Co. Ltd. | Elental | Branched-chain Amino Acid Preparation | Nutritional Deficiency | YEN | Millions | 6,600 | New Launch | 63 | New Launch | 63 | New Launch |
Eisai Co. Ltd. | Warfarin | Warfarin | Cardiovascular Diseases | YEN | Millions | 6,200 | 7,000 | 60 | 67 | -8 | -11 |
Eisai Co. Ltd. | Livact | Branched-chain Amino Acid Preparation | Nutritional Deficiency | YEN | Millions | 6,200 | New Launch | 60 | New Launch | 60 | New Launch |
Eisai Co. Ltd. | Lenvima | Lenvatinib | Oncology | YEN | Millions | 29,800 | 18,900 | 286 | 181 | 105 | 58 |
Eisai Co. Ltd. | Fycompa | Perampanel | Neurological/Mental Disorders | YEN | Millions | 13,400 | 9,600 | 129 | 92 | 36 | 40 |
Eisai Co. Ltd. | Zebinix | Eslicarbazepine Acetate | Neurological/Mental Disorders | YEN | Millions | 5,100 | 3,600 | 49 | 35 | 14 | 42 |
Eisai Co. Ltd. | Zonegran | Zonisamide | Neurological/Mental Disorders | YEN | Millions | 4,500 | 5,500 | 43 | 53 | -10 | -18 |
Eisai Co. Ltd. | Inovelan | Rufinamide | Neurological/Mental Disorders | YEN | Millions | 2,200 | 1,900 | 21 | 18 | 3 | 16 |
Eisai Co. Ltd. | Stronger Neo-Minophagen C and Glycyron | Glycyrrhizin preparation | Gastrointestinal Disorders | YEN | Millions | 9,900 | 8,500 | 95 | 82 | 13 | 16 |
Eisai Co. Ltd. | Chocola BB Group | Vitamin B2 | | YEN | Millions | 13,700 | 12,300 | 132 | 118 | 13 | 11 |
Eisai Co. Ltd. | Aloxi | Palonosetron | Anti-emetic | YEN | Millions | 44,800 | 48,400 | 430 | 465 | -35 | -7 |
Eisai Co. Ltd. | Banzel | Rufinamide | Neurological/Mental Disorders | YEN | Millions | 16,600 | 13,200 | 159 | 127 | 33 | 26 |
Eisai Co. Ltd. | AcipHex | Rabeprazole | Gastrointestinal Disorders | YEN | Millions | 6,500 | 7,100 | 62 | 68 | -6 | -8 |
Eisai Co. Ltd. | Belviq | Lorcaserin | Weight Loss and Obesity | YEN | Millions | 3,600 | 3,600 | 35 | 35 | 0 | 0.0 |
Eisai Co. Ltd. | Actonel | Risedronic Acid | Bone and Joint Diseases | YEN | Millions | Not Available | 5,700 | Not Available | 55 | -55 | -101 |
Eisai Co. Ltd. | Others | | | YEN | Millions | 152,840 | 149,600 | 1,467 | 1,436 | 31 | 2 |
Eisai Co. Ltd. | Total Revenue | | | YEN | Millions | 569,800 | 530,700 | 5,470 | 5,095 | 375 | 7 |
Eli Lilly | Zyprexa | Olanzapine | Neurological/Mental Disorders | USD | Millions | 581 | 725 | 581 | 725 | -144 | -20 |
Eli Lilly | Cymbalta | Duloxetine | Neurological/Mental Disorders | USD | Millions | 757 | 931 | 757 | 931 | -173 | -19 |
Eli Lilly | Strattera | Atomoxetine | Neurological/Mental Disorders | USD | Millions | 618 | 855 | 618 | 855 | -237 | -28 |
Eli Lilly | Other Neuroscience | | | USD | Millions | 214 | 210 | 214 | 210 | 5 | 2 |
Eli Lilly | Total Neuroscience | | | USD | Millions | 2,171 | 2,720 | 2,171 | 2,720 | -549 | -20 |
Eli Lilly | Taltz | Ixekizumab | Autoimmune Disorders | USD | Millions | 559 | 113 | 559 | 113 | 446 | 394 |
Eli Lilly | Other Immunology | | | USD | Millions | 46 | Not Available | 46 | Not Available | 46 | Not Available |
Eli Lilly | Total Immunology | | | USD | Millions | 605 | 113 | 605 | 113 | 492 | 435 |
Eli Lilly | Humalog | Insulin Lispro | Diabetes | USD | Millions | 2,865 | 2,769 | 2,865 | 2,769 | 96 | 3 |
Eli Lilly | Humulin | Insulin Isophane | Diabetes | USD | Millions | 1,335 | 1,366 | 1,335 | 1,366 | -31 | -2 |
Eli Lilly | Forteo | Teriparatide | Bone and Joint Diseases | USD | Millions | 1,749 | 1,500 | 1,749 | 1,500 | 249 | 17 |
Eli Lilly | Trajenta | Linagliptin | Diabetes | USD | Millions | 538 | 437 | 538 | 437 | 101 | 23 |
Eli Lilly | Jardiance | Empagliflozin | Diabetes | USD | Millions | 448 | 202 | 448 | 202 | 246 | 122 |
Eli Lilly | Trulicity | Dulaglutide | Diabetes | USD | Millions | 2,030 | 926 | 2,030 | 926 | 1,104 | 119 |
Eli Lilly | Basaglar | Insulin Glargine | Diabetes | USD | Millions | 432 | 86 | 432 | 86 | 346 | 402 |
Eli Lilly | Other Endocrinology | | | USD | Millions | 688 | 798 | 688 | 798 | -110 | -14 |
Eli Lilly | Total Endocrinology | | | USD | Millions | 10,085 | 7,328 | 10,085 | 7,328 | 2,758 | 38 |
Eli Lilly | Alimta | Pemetrexed | Oncology | USD | Millions | 2,063 | 2,283 | 2,063 | 2,283 | -221 | -10 |
Eli Lilly | Cyramza | Ramucirumab | Oncology | USD | Millions | 758 | 614 | 758 | 614 | 144 | 23 |
Eli Lilly | Erbitux | Cetuximab | Oncology | USD | Millions | 646 | 687 | 646 | 687 | -41 | -6 |
Eli Lilly | Other Oncology | | | USD | Millions | 345 | 137 | 345 | 137 | 208 | 151 |
Eli Lilly | Total Oncology | | | USD | Millions | 3,812 | 3,584 | 3,812 | 3,584 | 228 | 6 |
Eli Lilly | Cialis | Tadalafil | Sexual Health | USD | Millions | 2,323 | 2,472 | 2,323 | 2,472 | -149 | -6 |
Eli Lilly | Effient | Prasugrel | Cardiovascular Diseases | USD | Millions | 389 | 535 | 389 | 535 | -146 | -27 |
Eli Lilly | Other Cardiovascular | | | USD | Millions | 159 | 219 | 159 | 219 | -60 | -27 |
Eli Lilly | Total Cardiovascular | | | USD | Millions | 2,871 | 3,057 | 2,871 | 3,057 | -186 | -6 |
Eli Lilly | Other Human Pharmaceutical Products | | | USD | Millions | 241 | 201 | 241 | 201 | 41 | 20 |
Eli Lilly | Total Pharmaceuticals | | | USD | Millions | 19,786 | 18,064 | 19,786 | 18,064 | 1,722 | 10 |
Eli Lilly | Total Animal Health | | | USD | Millions | 3,086 | 3,158 | 3,086 | 3,158 | -73 | -2 |
Eli Lilly | Total Revenues | | | USD | Millions | 22,871 | 21,222 | 22,871 | 21,222 | 1,649 | 8 |
Endo Pharmaceuticals | Xiaflex | Collagenase Clostridium Histolyticum | Bone and Joint Diseases | USD | Millions | 213 | 190 | 213 | 190 | 24 | 12 |
Endo Pharmaceuticals | Supprelin LA | Histrelin Acetate | Oncology | USD | Millions | 86 | 79 | 86 | 79 | 8 | 10 |
Endo Pharmaceuticals | Other Specialty | | | USD | Millions | 153 | 139 | 153 | 139 | 15 | 11 |
Endo Pharmaceuticals | Total Specialty Products | | | USD | Millions | 453 | 407 | 453 | 407 | 46 | 11 |
Endo Pharmaceuticals | Opana ER | Oxymorphone Hydrochloride | Anti-inflammatory | USD | Millions | 84 | 159 | 84 | 159 | -75 | -47 |
Endo Pharmaceuticals | Percocet | Oxycodone/Paracetamol | Anti-inflammatory | USD | Millions | 125 | 139 | 125 | 139 | -14 | -10 |
Endo Pharmaceuticals | Voltaren | Diclofenac Sodium | Bone and Joint Diseases | USD | Millions | 69 | 101 | 69 | 101 | -32 | -32 |
Endo Pharmaceuticals | Lidoderm | Lidocaine | Anti-inflammatory | USD | Millions | 52 | 88 | 52 | 88 | -36 | -41 |
Endo Pharmaceuticals | Other Established | | | USD | Millions | 175 | 273 | 175 | 273 | -98 | -36 |
Endo Pharmaceuticals | Total Established Products | | | USD | Millions | 505 | 759 | 505 | 759 | -255 | -34 |
Endo Pharmaceuticals | Total U.S. Branded Pharmaceuticals | | | USD | Millions | 958 | 1,166 | 958 | 1,166 | -209 | -18 |
Endo Pharmaceuticals | U.S. Generics Base | | | USD | Millions | 830 | 1,230 | 830 | 1,230 | -400 | -33 |
Endo Pharmaceuticals | Sterile Injectables | | | USD | Millions | 654 | 531 | 654 | 531 | 123 | 23 |
Endo Pharmaceuticals | New Launches and Alternative Dosages | | | USD | Millions | 797 | 804 | 797 | 804 | -7 | -1 |
Endo Pharmaceuticals | Total U.S. Generic Pharmaceuticals | | | USD | Millions | 2,281 | 2,565 | 2,281 | 2,565 | -284 | -11 |
Endo Pharmaceuticals | Total International Pharmaceuticals | | | USD | Millions | 230 | 279 | 230 | 279 | -49 | -18 |
Endo Pharmaceuticals | Total Revenues | | | USD | Millions | 3,469 | 4,010 | 3,469 | 4,010 | -541 | -14 |
Fresenius SE & Co. KGaA | Fresenius Medical Care | | | USD | Millions | 17,784 | 16,570 | 17,784 | 16,570 | 1,214 | 7 |
Fresenius SE & Co. KGaA | Fresenius Kabi | | | USD | Millions | 6,358 | 6,007 | 6,358 | 6,007 | 351 | 6 |
Fresenius SE & Co. KGaA | Fresenius Helios | | | USD | Millions | 8,668 | 5,843 | 8,668 | 5,843 | 2,825 | 48 |
Fresenius SE & Co. KGaA | Fresenius Vamed | | | USD | Millions | 1,228 | 1,160 | 1,228 | 1,160 | 68 | 6 |
Fresenius SE & Co. KGaA | Total Revenues | | | USD | Millions | 34,038 | 29,083 | 34,038 | 29,083 | 4,955 | 17 |
Gilead | Sovaldi | Sofosbuvir | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 964 | 4,001 | 964 | 4,001 | -3,037 | -76 |
Gilead | Atripla | Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,806 | 2,605 | 1,806 | 2,605 | -799 | -31 |
Gilead | Truvada | Emtricitabine, and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 3,134 | 3,566 | 3,134 | 3,566 | -432 | -12 |
Gilead | Harvoni | Ledipasvir and Sofosbuvir | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 4,370 | 9,081 | 4,370 | 9,081 | -4,711 | -52 |
Gilead | Complera/Eviplera | Rilpivirine, Emtricitabine, and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 966 | 1,457 | 966 | 1,457 | -491 | -34 |
Gilead | Stribild | Cobicistat, Elvitegravir, Emtricitabine and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,053 | 1,914 | 1,053 | 1,914 | -861 | -45 |
Gilead | Viread | Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,046 | 1,186 | 1,046 | 1,186 | -140 | -12 |
Gilead | Epclusa | Sofosbuvir and Velpatasvir | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 3,510 | 1,752 | 3,510 | 1,752 | 1,758 | 100 |
Gilead | Odefsey | Emtricitabine, Rilpivirine, and Tenofovir Alafenamide | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,106 | 329 | 1,106 | 329 | 777 | 236 |
Gilead | Descovy | Emtricitabine and Tenofovir Alafenamide | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,218 | 298 | 1,218 | 298 | 920 | 309 |
Gilead | Vosevi | Sofosbuvir 400 mg/Velpatasvir 100 mg/Voxilaprevir 100 mg | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 293 | New Launch | 293 | New Launch | 293 | New Launch |
Gilead | Genvoya | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 3,674 | 1,484 | 3,674 | 1,484 | 2,190 | 148 |
Gilead | Other Antiviral | | | USD | Millions | 196 | 72 | 196 | 72 | 124 | 172 |
Gilead | Total Antiviral Products | | | USD | Millions | 23,336 | 27,745 | 23,336 | 27,745 | -4,409 | -16 |
Gilead | Letairis | Ambrisentan | Cardiovascular Diseases | USD | Millions | 887 | 819 | 887 | 819 | 68 | 8 |
Gilead | Ranexa | Ranolazine | Cardiovascular Diseases | USD | Millions | 717 | 677 | 717 | 677 | 40 | 6 |
Gilead | AmBisome | Amphotericin B | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 366 | 356 | 366 | 356 | 10 | 3 |
Gilead | Zydelig | Idelalisib | Oncology | USD | Millions | 149 | 168 | 149 | 168 | -19 | -11 |
Gilead | Others | | | USD | Millions | 207 | 188 | 207 | 188 | 19 | 10 |
Gilead | Total Other Products | | | USD | Millions | 2,326 | 2,208 | 2,326 | 2,208 | 118 | 5 |
Gilead | Total Product Sales | | | USD | Millions | 25,662 | 29,953 | 25,662 | 29,953 | -4,291 | -14 |
Gilead | Royalty Contract and Other Revenues | | | USD | Millions | 445 | 437 | 445 | 437 | 8 | 2 |
Gilead | Total Revenues | | | USD | Millions | 26,107 | 30,390 | 26,107 | 30,390 | -4,283 | -14 |
GlaxoSmithKline | Anoro Ellipta | Umeclidinium and Vilanterol | Respiratory Disorders | GBP | Millions | 342 | 201 | 482 | 283 | 199 | 70 |
GlaxoSmithKline | Avamys/Veramyst | Fluticasone Furoate | Respiratory Disorders | GBP | Millions | 281 | 277 | 396 | 391 | 6 | 1 |
GlaxoSmithKline | Flixotide/Flovent | Fluticasone Propionate | Respiratory Disorders | GBP | Millions | 596 | 637 | 840 | 898 | -58 | -6 |
GlaxoSmithKline | Relvar/Breo Ellipta | Fluticasone Furoate | Respiratory Disorders | GBP | Millions | 1,006 | 620 | 1,418 | 874 | 544 | 62 |
GlaxoSmithKline | Seretide/Advair | Salmeterol | Respiratory Disorders | GBP | Millions | 3,130 | 3,485 | 4,413 | 4,914 | -501 | -10 |
GlaxoSmithKline | Incruse Ellipta | Umeclidinium | Respiratory Disorders | GBP | Millions | 201 | 114 | 283 | 161 | 123 | 76 |
GlaxoSmithKline | Nucala | Mepolizumab | Respiratory Disorders | GBP | Millions | 344 | 102 | 485 | 144 | 341 | 237 |
GlaxoSmithKline | Arnuity Ellipta | Fluticasone Furoate | Respiratory Disorders | GBP | Millions | 35 | 15 | 49 | 21 | 28 | 133 |
GlaxoSmithKline | Ventolin | Albuterol | Respiratory Disorders | GBP | Millions | 767 | 785 | 1,081 | 1,107 | -25 | -2 |
GlaxoSmithKline | Trelegy Ellipta | Fluticasone Furoate, Vilanterol Trifenatate and Umeclidinium Bromide | Respiratory Disorders | GBP | Millions | 2 | 0 | 3 | 0 | 3 | New Launch |
GlaxoSmithKline | Others | | | GBP | Millions | 287 | 274 | 405 | 386 | 18 | 5 |
GlaxoSmithKline | Total Respiratory | | | GBP | Millions | 6,991 | 6,510 | 9,857 | 9,179 | 678 | 7 |
GlaxoSmithKline | Benlysta | Belimumab | Rare Diseases | GBP | Millions | 375 | 306 | 529 | 431 | 97 | 23 |
GlaxoSmithKline | Others | | | GBP | Millions | 2 | 34 | 3 | 48 | -45 | -94 |
GlaxoSmithKline | Total Immuno-Inflammation | | | GBP | Millions | 377 | 340 | 532 | 479 | 52 | 11 |
GlaxoSmithKline | Epzicom/Kivexa | Abacavir and Lamivudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | Millions | 234 | 568 | 330 | 801 | -471 | -59 |
GlaxoSmithKline | Selzentry | Maraviroc | Infectious Diseases (HIV, Hepatitis etc.) | GBP | Millions | 128 | 125 | 180 | 176 | 4 | 2 |
GlaxoSmithKline | Tivicay | Dolutegravir | Infectious Diseases (HIV, Hepatitis etc.) | GBP | Millions | 1,404 | 953 | 1,980 | 1,344 | 636 | 47 |
GlaxoSmithKline | Triumeq | Abacavir, Dolutegravir and Lamivudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | Millions | 2,461 | 1,735 | 3,470 | 2,446 | 1,024 | 42 |
GlaxoSmithKline | Juluca | Dolutegravir and Rilpivirine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | Millions | 5 | 0 | 7 | 0 | 7 | New Launch |
GlaxoSmithKline | Others | | | GBP | Millions | 118 | 175 | 166 | 247 | -80 | -33 |
GlaxoSmithKline | Total HIV | | | GBP | Millions | 4,350 | 3,556 | 6,134 | 5,014 | 1,120 | 22 |
GlaxoSmithKline | Dermatology | | | GBP | Millions | 456 | 393 | 643 | 554 | 89 | 16 |
GlaxoSmithKline | Augmentin | Amoxicillin and Clavulanate Potassium | Anti-bacterial | GBP | Millions | 587 | 563 | 828 | 794 | 34 | 4 |
GlaxoSmithKline | Avodart | Dutasteride | Urology | GBP | Millions | 613 | 635 | 864 | 895 | -31 | -3 |
GlaxoSmithKline | Eperzan/Tanzeum | Albiglutide | Diabetes | GBP | Millions | 87 | 121 | 123 | 171 | -48 | -28 |
GlaxoSmithKline | Coreg | Carvedilol | Cardiovascular Diseases | GBP | Millions | 134 | 131 | 189 | 185 | 4 | 2 |
GlaxoSmithKline | Imigran/Imitrex | Sumatriptan Succinate | Neurological/Mental Disorders | GBP | Millions | 168 | 177 | 237 | 250 | -13 | -5 |
GlaxoSmithKline | Lamictal | Lamotrigine | Neurological/Mental Disorders | GBP | Millions | 650 | 614 | 917 | 866 | 51 | 6 |
GlaxoSmithKline | Requip | Ropinirole | Neurological/Mental Disorders | GBP | Millions | 110 | 116 | 155 | 164 | -8 | -5 |
GlaxoSmithKline | Serevent | Salmeterol | Respiratory Disorders | GBP | Millions | 96 | 96 | 135 | 135 | 0 | 0.0 |
GlaxoSmithKline | Seroxat/Paxil | Paroxetine Hydrochloride Hemihydrate | Neurological/Mental Disorders | GBP | Millions | 184 | 206 | 259 | 290 | -31 | -11 |
GlaxoSmithKline | Valtrex | Valacyclovir | Infectious Diseases (HIV, Hepatitis etc.) | GBP | Millions | 128 | 118 | 180 | 166 | 14 | 8 |
GlaxoSmithKline | Zeffix | Lamivudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | Millions | 89 | 111 | 125 | 157 | -31 | -20 |
GlaxoSmithKline | Others | | | GBP | Millions | 2,256 | 2,417 | 3,181 | 3,408 | -227 | -7 |
GlaxoSmithKline | Established Products | | | GBP | Millions | 5,558 | 5,698 | 7,837 | 8,034 | -197 | -2 |
GlaxoSmithKline | Total Pharmaceuticals | | | GBP | Millions | 17,276 | 16,104 | 24,359 | 22,707 | 1,653 | 7 |
GlaxoSmithKline | Bexsero | Meningococcal Vaccine | Vaccine | GBP | Millions | 556 | 390 | 784 | 550 | 234 | 43 |
GlaxoSmithKline | Menveo | Meningococcal Vaccine | Vaccine | GBP | Millions | 274 | 202 | 386 | 285 | 102 | 36 |
GlaxoSmithKline | Other | | | GBP | Millions | 60 | 70 | 85 | 99 | -14 | -14 |
GlaxoSmithKline | Total Meningitis | | | GBP | Millions | 890 | 662 | 1,255 | 933 | 321 | 34 |
GlaxoSmithKline | Fluarix/FluLaval | Influenza Vaccine | Vaccine | GBP | Millions | 488 | 414 | 688 | 584 | 104 | 18 |
GlaxoSmithKline | Total Influenza | | | GBP | Millions | 488 | 414 | 688 | 584 | 104 | 18 |
GlaxoSmithKline | Shingrix | Zoster Vaccine Recombinant, Adjuvanted | Vaccine | GBP | Millions | 22 | 0 | 31 | 0 | 31 | New Launch |
GlaxoSmithKline | Total Shingles | | | GBP | Millions | 22 | New Launch | 31 | New Launch | 31 | New Launch |
GlaxoSmithKline | Boostrix | Diphtheria, Tetanus Acellular, and Pertussis | Vaccine | GBP | Millions | 560 | 470 | 790 | 663 | 127 | 19 |
GlaxoSmithKline | Cervarix | Human Papillomavirus Bivalent | Vaccine | GBP | Millions | 134 | 81 | 189 | 114 | 75 | 65 |
GlaxoSmithKline | Hepatitis | Vaccine | Vaccine | GBP | Millions | 693 | 602 | 977 | 849 | 128 | 15 |
GlaxoSmithKline | Infanrix/Pediarix | Diphtheria, Tetanus Acellular, and Pertussis | Vaccine | GBP | Millions | 743 | 769 | 1,048 | 1,084 | -37 | -3 |
GlaxoSmithKline | Rotarix | Vaccine | Vaccine | GBP | Millions | 524 | 469 | 739 | 661 | 78 | 12 |
GlaxoSmithKline | Priorix/Priorix Tetra/Varilrix | Vaccine | Vaccine | GBP | Millions | 301 | 300 | 424 | 423 | 1 | 0.3 |
GlaxoSmithKline | Synflorix | Vaccine | Vaccine | GBP | Millions | 509 | 504 | 718 | 711 | 7 | 1 |
GlaxoSmithKline | Others | | | GBP | Millions | 296 | 321 | 417 | 453 | -35 | -8 |
GlaxoSmithKline | Established Vaccines | | | GBP | Millions | 3,760 | 3,516 | 5,302 | 4,958 | 344 | 7 |
GlaxoSmithKline | Total Vaccines | | | GBP | Millions | 5,160 | 4,592 | 7,276 | 6,475 | 801 | 12 |
GlaxoSmithKline | Consumer Healthcare Turnover | | | GBP | Millions | 7,750 | 7,193 | 10,928 | 10,142 | 785 | 8 |
GlaxoSmithKline | Total Sales | | | GBP | Millions | 30,186 | 27,889 | 42,562 | 39,323 | 3,239 | 8 |
Ipsen | Decapeptyl | Triptorelin | Hormonal Disorders | EURO | Millions | 349 | 340 | 432 | 421 | 11 | 3 |
Ipsen | Somatuline | Lanreotide | Oncology | EURO | Millions | 703 | 538 | 871 | 667 | 204 | 31 |
Ipsen | Cabometyx | Cabozantinib | Oncology | EURO | Millions | 52 | 7 | 64 | 9 | 55 | 618 |
Ipsen | Onivyde | Irinotecan | Oncology | EURO | Millions | 57 | 0 | 71 | 0 | 71 | New Launch |
Ipsen | Other Oncology | | | EURO | Millions | 25 | 20 | 31 | 24 | 7 | 30 |
Ipsen | Oncology | | | EURO | Millions | 1,185 | 905 | 1,470 | 1,122 | 348 | 31 |
Ipsen | Dysport | Abobotulinumtoxin A | Lower Limb Spasticity | EURO | Millions | 328 | 285 | 407 | 353 | 54 | 15 |
Ipsen | Neuroscience | | | EURO | Millions | 332 | 287 | 411 | 356 | 56 | 16 |
Ipsen | NutropinAq | Somatropin (rDNA origin) | Growth Hormone | EURO | Millions | 52 | 58 | 64 | 72 | -7 | -10 |
Ipsen | Increlex | Mecasermin | Metabolic Disorders | EURO | Millions | 23 | 24 | 28 | 29 | -1 | -3 |
Ipsen | Rare Diseases | | | EURO | Millions | 75 | 81 | 93 | 101 | -8 | -8 |
Ipsen | Total Specialty Care | | | EURO | Millions | 1,592 | 1,273 | 1,974 | 1,579 | 395 | 25 |
Ipsen | Smecta | Dioctahedral Smectite | Gastrointestinal Disorders | EURO | Millions | 116 | 111 | 143 | 138 | 6 | 4 |
Ipsen | Fortrans/Eziclen | Macrogol | Gastrointestinal Disorders | EURO | Millions | 32 | 27 | 40 | 33 | 7 | 20 |
Ipsen | Etiasa | Mesalazine | Gastrointestinal Disorders | EURO | Millions | 18 | 29 | 22 | 36 | -14 | -39 |
Ipsen | Forlax | Macrogol | Gastrointestinal Disorders | EURO | Millions | 42 | 39 | 52 | 49 | 3 | 7 |
Ipsen | Tanakan | Ginkgo Biloba Extract | Neurological/Mental Disorders | EURO | Millions | 41 | 44 | 51 | 54 | -3 | -5 |
Ipsen | Other Consumer Healthcare | | | EURO | Millions | 68 | 62 | 84 | 76 | 8 | 10 |
Ipsen | Consumer Healthcare | | | EURO | Millions | 317 | 312 | 393 | 386 | 6 | 2 |
Ipsen | Group sales | | | EURO | Millions | 1,909 | 1,585 | 2,367 | 1,965 | 402 | 20 |
Ipsen | Other Revenues | | | EURO | Millions | 103 | 87 | 128 | 107 | 20 | 19 |
Ipsen | Total Sales | | | EURO | Millions | 3,920 | 3,256 | 4,861 | 4,037 | 824 | 20 |
Johnson & Johnson | Remicade | Infliximab | Autoimmune Disorders | USD | Millions | 6,315 | 6,966 | 6,315 | 6,966 | -651 | -9 |
Johnson & Johnson | Simponi/Simponi Aria | Golimumab | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 1,833 | 1,745 | 1,833 | 1,745 | 88 | 5 |
Johnson & Johnson | Stelara | Ustekinumab | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 4,011 | 3,232 | 4,011 | 3,232 | 779 | 24 |
Johnson & Johnson | Other Products | | | USD | Millions | 85 | 25 | 85 | 25 | 60 | 240 |
Johnson & Johnson | Total Immunology | | | USD | Millions | 12,244 | 11,968 | 12,244 | 11,968 | 276 | 2 |
Johnson & Johnson | Edurant | Rilpivirine | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 714 | 573 | 714 | 573 | 141 | 25 |
Johnson & Johnson | Prezista | Darunavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,821 | 1,851 | 1,821 | 1,851 | -30 | -2 |
Johnson & Johnson | Other Products | | | USD | Millions | 619 | 784 | 619 | 784 | -165 | -21 |
Johnson & Johnson | Total Infectious Diseases | | | USD | Millions | 3,154 | 3,208 | 3,154 | 3,208 | -54 | -2 |
Johnson & Johnson | Concerta | Methylphenidate | Neurological/Mental Disorders | USD | Millions | 791 | 863 | 791 | 863 | -72 | -8 |
Johnson & Johnson | Invega Sustenna/Xeplion/Trinza/Trevicta | Paliperidone Palmitate | Neurological/Mental Disorders | USD | Millions | 2,569 | 2,214 | 2,569 | 2,214 | 355 | 16 |
Johnson & Johnson | Risperdal Consta | Risperidone | Neurological/Mental Disorders | USD | Millions | 805 | 893 | 805 | 893 | -88 | -10 |
Johnson & Johnson | Other Products | | | USD | Millions | 1,821 | 2,115 | 1,821 | 2,115 | -294 | -14 |
Johnson & Johnson | Total Neuroscience | | | USD | Millions | 5,986 | 6,085 | 5,986 | 6,085 | -99 | -2 |
Johnson & Johnson | Darzalex | Daratumumab | Oncology | USD | Millions | 1,242 | 572 | 1,242 | 572 | 670 | 117 |
Johnson & Johnson | Imbruvica | Ibrutinib | Oncology | USD | Millions | 1,893 | 1,251 | 1,893 | 1,251 | 642 | 51 |
Johnson & Johnson | Velcade | Bortezomib | Oncology | USD | Millions | 1,114 | 1,224 | 1,114 | 1,224 | -110 | -9 |
Johnson & Johnson | Zytiga | Abiraterone Acetate | Oncology | USD | Millions | 2,505 | 2,260 | 2,505 | 2,260 | 245 | 11 |
Johnson & Johnson | Other Products | | | USD | Millions | 504 | 500 | 504 | 500 | 4 | 1 |
Johnson & Johnson | Total Oncology | | | USD | Millions | 7,258 | 5,807 | 7,258 | 5,807 | 1,451 | 25 |
Johnson & Johnson | Invokana/Invokamet | Canagliflozin/ Canagliflozin and Metformin HCl | Diabetes | USD | Millions | 1,111 | 1,407 | 1,111 | 1,407 | -296 | -21 |
Johnson & Johnson | Procrit/Eprex | Epoetin Alfa | Blood Disorders | USD | Millions | 972 | 1,105 | 972 | 1,105 | -133 | -12 |
Johnson & Johnson | Xarelto | Rivaroxaban | Cardiovascular Diseases | USD | Millions | 2,500 | 2,288 | 2,500 | 2,288 | 212 | 9 |
Johnson & Johnson | Other Products | | | USD | Millions | 1,704 | 1,596 | 1,704 | 1,596 | 108 | 7 |
Johnson & Johnson | Total Cardiovascular/Metabolic Disorders/Other | | | USD | Millions | 6,287 | 6,396 | 6,287 | 6,396 | -109 | -2 |
Johnson & Johnson | Opsumit | Macitentan | Cardiovascular Diseases | USD | Millions | 573 | 878 | 573 | 878 | -305 | -35 |
Johnson & Johnson | Tracleer | Bosentan | Cardiovascular Diseases | USD | Millions | 403 | 1,078 | 403 | 1,078 | -675 | -63 |
Johnson & Johnson | Uptravi | Selexipag | Cardiovascular Diseases | USD | Millions | 263 | 259 | 263 | 259 | 4 | 2 |
Johnson & Johnson | Other Products | | | USD | Millions | 88 | 335 | 88 | 335 | -247 | -74 |
Johnson & Johnson | Total Pulmonary Hypertension | | | USD | Millions | 1,327 | Actelion products acquired by J & J | 1,327 | Actelion products acquired by J & J | 1,327 | Actelion products acquired by J & J |
Johnson & Johnson | Total Pharmaceuticals | | | USD | Millions | 36,256 | 33,464 | 36,256 | 33,464 | 2,792 | 8 |
Johnson & Johnson | Consumer HealthCare | | | USD | Millions | 13,602 | 13,307 | 13,602 | 13,307 | 295 | 2 |
Johnson & Johnson | Medical Devices | | | USD | Millions | 26,592 | 25,119 | 26,592 | 25,119 | 1,473 | 6 |
Johnson & Johnson | Total All Divisions | | | USD | Millions | 76,450 | 71,890 | 76,450 | 71,890 | 4,560 | 6 |
Kyowa Kirin | Nesp | Darbepoetin Alfa | Renal Disorders | YEN | Millions | 62,000 | 61,300 | 595 | 588 | 7 | 1 |
Kyowa Kirin | Espo | Epoetin Alfa | Renal Disorders | YEN | Millions | 1,400 | 1,600 | 13 | 15 | -2 | -13 |
Kyowa Kirin | Regpara | Cinacalcet Hydrochloride | Hormonal Disorders | YEN | Millions | 20,700 | 21,800 | 199 | 209 | -11 | -5 |
Kyowa Kirin | Rocaltrol | Calcitriol | Hormonal Disorders | YEN | Millions | 4,100 | 4,200 | 39 | 40 | -1 | -2 |
Kyowa Kirin | Onglyza | Saxagliptin | Diabetes | YEN | Millions | 7,300 | 6,300 | 70 | 60 | 10 | 16 |
Kyowa Kirin | Coniel | Benidipine | Cardiovascular Diseases | YEN | Millions | 6,300 | 7,600 | 60 | 73 | -12 | -17 |
Kyowa Kirin | G-Lasta | Pegfilgrastim | Blood Disorders | YEN | Millions | 18,100 | 15,500 | 174 | 149 | 25 | 17 |
Kyowa Kirin | Gran | Filgrastim | Blood Disorders | YEN | Millions | 8,500 | 9,000 | 82 | 86 | -5 | -6 |
Kyowa Kirin | Fentos | Fentanyl Transdermal | Persistent Pain | YEN | Millions | 6,000 | 6,300 | 58 | 60 | -3 | -5 |
Kyowa Kirin | Poteligeo | Mogamulizumab | Oncology | YEN | Millions | 1,900 | 1,900 | 18 | 18 | 0 | 0.0 |
Kyowa Kirin | Romiplate | Romiplostim | Blood Disorders | YEN | Millions | 3,400 | 3,300 | 33 | 32 | 1 | 3 |
Kyowa Kirin | Allelock | Olopatadine Hydrochloride | Anti-allergic | YEN | Millions | 15,900 | 18,200 | 153 | 175 | -22 | -13 |
Kyowa Kirin | Patanol | Olopatadine Hydrochloride | Anti-allergic | YEN | Millions | 12,800 | 13,000 | 123 | 125 | -2 | -2 |
Kyowa Kirin | Asacol | Mesalazine | Gastrointestinal Disorders | YEN | Millions | 4,200 | 4,800 | 40 | 46 | -6 | -13 |
Kyowa Kirin | Dovobet | Calcipotriol Hydrate + Betamethasone Dipropionate | Dermatology | YEN | Millions | 5,300 | 5,500 | 51 | 53 | -2 | -4 |
Kyowa Kirin | Lumicef | Brodalumab | Dermatology | YEN | Millions | 1,000 | 100 | 10 | 1 | 9 | 900 |
Kyowa Kirin | Nouriast | Istradefylline | Neurological/Mental Disorders | YEN | Millions | 8,500 | 7,300 | 82 | 70 | 12 | 16 |
Kyowa Kirin | Depakene | Sodium Valproate | Neurological/Mental Disorders | YEN | Millions | 6,500 | 7,300 | 62 | 70 | -8 | -11 |
Kyowa Kirin | Nauzelin | Domperidone | Gastrointestinal Disorders | YEN | Millions | 2,500 | 3,200 | 24 | 31 | -7 | -22 |
Kyowa Kirin | Neulasta/Peglasta | Pegfilgrastim | Blood Disorders | YEN | Millions | 2,000 | 1,500 | 19 | 14 | 5 | 33 |
Kyowa Kirin | Abstral | Fentanyl Sublingual | Oncology | YEN | Millions | 11,900 | 10,600 | 114 | 102 | 12 | 12 |
Kyowa Kirin | PecFent | Fentanyl Intranasal Spray | Oncology | YEN | Millions | 4,100 | 4,000 | 39 | 38 | 1 | 3 |
Kyowa Kirin | Mitomycin-C | Mitomycin | Oncology | YEN | Millions | 3,400 | 3,200 | 33 | 31 | 2 | 6 |
Kyowa Kirin | Sancuso | Granisetron Transdermal System | Anti-emetic | YEN | Millions | 3,000 | 3,100 | 29 | 30 | -1 | -3 |
Kyowa Kirin | Moventig | Naloxegol | Opioid-induced Constipation | YEN | Millions | 800 | 300 | 8 | 3 | 5 | 167 |
Kyowa Kirin | Tostran/Fortesta | Testosterone Topical Tostrex | Hormonal Disorders | YEN | Millions | 2,200 | 2,400 | 21 | 23 | -2 | -8 |
Kyowa Kirin | Rectogesic | Nitroglycerin Topical | Urology | YEN | Millions | 1,600 | 1,700 | 15 | 16 | -1 | -6 |
Kyowa Kirin | Adcal-D3 | Calcium Carbonate, Cholecalciferol | Bone and Joint Diseases | YEN | Millions | 3,600 | 3,900 | 35 | 37 | -3 | -8 |
Kyowa Kirin | Technology out-licensing | | | YEN | Millions | 18,400 | 12,700 | 177 | 122 | 55 | 45 |
Kyowa Kirin | Total Pharmaceuticals | | | YEN | Millions | 247,400 | 241,600 | 2,375 | 2,319 | 56 | 2 |
Kyowa Kirin | Others | | | YEN | Millions | 106,000 | 106,400 | 1,018 | 1,021 | -4 | -0.4 |
Kyowa Kirin | Total Revenues | | | YEN | Millions | 353,400 | 348,000 | 3,393 | 3,341 | 52 | 2 |
Lundbeck | Abilify Maintena | Aripiprazole | Neurological/Mental Disorders | DKK | Millions | 1,331 | 1,114 | 226 | 189 | 37 | 19 |
Lundbeck | Brintellix/Trintellix | Vortioxetine | Neurological/Mental Disorders | DKK | Millions | 1,662 | 1,105 | 283 | 188 | 95 | 50 |
Lundbeck | Cipralex/Lexapro | Escitalopram | Neurological/Mental Disorders | DKK | Millions | 2,369 | 2,518 | 403 | 428 | -25 | -6 |
Lundbeck | Northera | Droxidopa | Neurological/Mental Disorders | DKK | Millions | 1,644 | 1,087 | 279 | 185 | 95 | 51 |
Lundbeck | Onfi | Clobazam | Neurological/Mental Disorders | DKK | Millions | 3,022 | 2,409 | 514 | 410 | 104 | 25 |
Lundbeck | Rexulti | Brexpiprazole | Neurological/Mental Disorders | DKK | Millions | 1,247 | 826 | 212 | 140 | 72 | 51 |
Lundbeck | Sabril | Vigabatrin | Neurological/Mental Disorders | DKK | Millions | 1,509 | 1,342 | 257 | 228 | 28 | 12 |
Lundbeck | Xenazine | Tetrabenazine | Neurological/Mental Disorders | DKK | Millions | 1,049 | 1,571 | 178 | 267 | -89 | -33 |
Lundbeck | Ebixa | Memantine Hydrochloride | Neurological/Mental Disorders | DKK | Millions | 460 | 487 | 78 | 83 | -5 | -6 |
Lundbeck | Other Pharmaceuticals | | | DKK | Millions | 2,542 | 2,850 | 432 | 485 | -52 | -11 |
Lundbeck | Other Revenues | | | DKK | Millions | 399 | 325 | 68 | 55 | 13 | 23 |
Lundbeck | Total Revenues | | | DKK | Millions | 17,234 | 15,634 | 2,930 | 2,658 | 272 | 10 |
Mallinckrodt Plc | Acthar | Corticotropin | Autoimmune Disorders | USD | Millions | 1,195 | 1,486 | 1,195 | 1,486 | -291 | -20 |
Mallinckrodt Plc | Inomax | Nitric Oxide | Respiratory Disorders | USD | Millions | 505 | 593 | 505 | 593 | -88 | -15 |
Mallinckrodt Plc | Ofirmev | Acetaminophen | Anti-inflammatory | USD | Millions | 303 | 357 | 303 | 357 | -54 | -15 |
Mallinckrodt Plc | Therakos Immunotherapy | | | USD | Millions | 215 | 255 | 215 | 255 | -40 | -16 |
Mallinckrodt Plc | Hemostasis products | | | USD | Millions | 55 | 56 | 55 | 56 | -1 | -2 |
Mallinckrodt Plc | Others | | | USD | Millions | 53 | 158 | 53 | 158 | -105 | -66 |
Mallinckrodt Plc | Specialty Brands | | | USD | Millions | 2,326 | 2,904 | 2,326 | 2,904 | -578 | -20 |
Mallinckrodt Plc | Hydrocodone (API) and Hydrocodone-containing tablets | Hydrocodone Bitartrate | Anti-inflammatory | USD | Millions | 85 | 170 | 85 | 170 | -85 | -50 |
Mallinckrodt Plc | Oxycodone (API) and Oxycodone-containing Tablets | Oxycodone | Anti-inflammatory | USD | Millions | 79 | 151 | 79 | 151 | -72 | -48 |
Mallinckrodt Plc | Methylphenidate ER | Methylphenidate Hydrochloride | Neurological/Mental Disorders | USD | Millions | 72 | 126 | 72 | 126 | -54 | -43 |
Mallinckrodt Plc | Other Controlled Substances | | | USD | Millions | 410 | 573 | 410 | 573 | -163 | -28 |
Mallinckrodt Plc | Others | | | USD | Millions | 194 | 219 | 194 | 219 | -25 | -12 |
Mallinckrodt Plc | Specialty Generics | | | USD | Millions | 840 | 1,025 | 840 | 1,025 | -185 | -18 |
Mallinckrodt Plc | Others | | | USD | Millions | 57 | 69 | 57 | 69 | -12 | -17 |
Mallinckrodt Plc | Total Sales | | | USD | Millions | 3,222 | 4,211 | 3,222 | 4,211 | -989 | -23 |
Merck & Co. Inc. | Zetia | Ezetimibe | Cardiovascular Diseases | USD | Millions | 1,344 | 2,560 | 1,344 | 2,560 | -1,216 | -48 |
Merck & Co. Inc. | Vytorin | Ezetimibe and Simvastatin | Cardiovascular Diseases | USD | Millions | 751 | 1,141 | 751 | 1,141 | -390 | -34 |
Merck & Co. Inc. | Atozet | Ezetimibe and Atorvastatin | Cardiovascular Diseases | USD | Millions | 225 | 147 | 225 | 147 | 78 | 53 |
Merck & Co. Inc. | Adempas | Riociguat | Cardiovascular Diseases | USD | Millions | 300 | 169 | 300 | 169 | 131 | 78 |
Merck & Co. Inc. | Total Cardiovascular | | | USD | Millions | 2,620 | 3,848 | 2,620 | 3,848 | -1,228 | -32 |
Merck & Co. Inc. | Januvia | Sitagliptin | Diabetes | USD | Millions | 3,737 | 3,908 | 3,737 | 3,908 | -171 | -4 |
Merck & Co. Inc. | Janumet | Metformin and Sitagliptin | Diabetes | USD | Millions | 2,158 | 2,201 | 2,158 | 2,201 | -43 | -2 |
Merck & Co. Inc. | Total Diabetes | | | USD | Millions | 5,895 | 6,109 | 5,895 | 6,109 | -214 | -4 |
Merck & Co. Inc. | NuvaRing | Ethinyl Estradiol and Etonogestrel | Sexual Health | USD | Millions | 761 | 777 | 761 | 777 | -16 | -2 |
Merck & Co. Inc. | Implanon/Nexplanon | Etonogestrel | Sexual Health | USD | Millions | 686 | 606 | 686 | 606 | 80 | 13 |
Merck & Co. Inc. | Follistim AQ | Follicle Stimulating Hormone | Sexual Health | USD | Millions | 298 | 355 | 298 | 355 | -57 | -16 |
Merck & Co. Inc. | Total General Medicine & Women's Health | | | USD | Millions | 1,745 | 1,738 | 1,745 | 1,738 | 7 | 0.4 |
Merck & Co. Inc. | Zepatier | Elbasvir and Grazoprevir | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,660 | 555 | 1,660 | 555 | 1,105 | 199 |
Merck & Co. Inc. | Total Hepatitis | | | USD | Millions | 1,660 | 555 | 1,660 | 555 | 1,105 | 199 |
Merck & Co. Inc. | Isentress | Raltegravir | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,204 | 1,387 | 1,204 | 1,387 | -183 | -13 |
Merck & Co. Inc. | Total HIV | | | USD | Millions | 1,204 | 1,387 | 1,204 | 1,387 | -183 | -13 |
Merck & Co. Inc. | Cubicin | Daptomycin | Anti-bacterial | USD | Millions | 382 | 1,087 | 382 | 1,087 | -705 | -65 |
Merck & Co. Inc. | Cancidas | Caspofungin | Anti-fungal | USD | Millions | 422 | 558 | 422 | 558 | -136 | -24 |
Merck & Co. Inc. | Invanz | Ertapenem | Anti-bacterial | USD | Millions | 602 | 561 | 602 | 561 | 41 | 7 |
Merck & Co. Inc. | Noxafil | Posaconazole | Anti-fungal | USD | Millions | 636 | 595 | 636 | 595 | 41 | 7 |
Merck & Co. Inc. | Bridion | Sugammadex | Neurological/Mental Disorders | USD | Millions | 704 | 482 | 704 | 482 | 222 | 46 |
Merck & Co. Inc. | Primaxin | Imipenem and Cilastatin | Anti-bacterial | USD | Millions | 280 | 297 | 280 | 297 | -17 | -6 |
Merck & Co. Inc. | Total Hospital Acute Care | | | USD | Millions | 3,026 | 3,580 | 3,026 | 3,580 | -554 | -15 |
Merck & Co. Inc. | Remicade | Infliximab | Autoimmune Disorders | USD | Millions | 837 | 1,268 | 837 | 1,268 | -431 | -34 |
Merck & Co. Inc. | Simponi | Golimumab | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 819 | 766 | 819 | 766 | 53 | 7 |
Merck & Co. Inc. | Total Immunology | | | USD | Millions | 1,656 | 2,034 | 1,656 | 2,034 | -378 | -19 |
Merck & Co. Inc. | Keytruda | Pembrolizumab | Oncology | USD | Millions | 3,809 | 1,402 | 3,809 | 1,402 | 2,407 | 172 |
Merck & Co. Inc. | Emend | Aprepitant | Oncology | USD | Millions | 556 | 549 | 556 | 549 | 7 | 1 |
Merck & Co. Inc. | Temodar | Temozolamide | Others | USD | Millions | 271 | 283 | 271 | 283 | -12 | -4 |
Merck & Co. Inc. | Total Oncology | | | USD | Millions | 4,636 | 2,234 | 4,636 | 2,234 | 2,402 | 108 |
Merck & Co. Inc. | Singulair | Montelukast Sodium | Respiratory Disorders | USD | Millions | 732 | 915 | 732 | 915 | -183 | -20 |
Merck & Co. Inc. | Nasonex | Mometasone Furoate | Respiratory Disorders | USD | Millions | 387 | 537 | 387 | 537 | -150 | -28 |
Merck & Co. Inc. | Dulera | Formoterol and Mometasone | Respiratory Disorders | USD | Millions | 287 | 436 | 287 | 436 | -149 | -34 |
Merck & Co. Inc. | Total Respiratory | | | USD | Millions | 1,406 | 1,888 | 1,406 | 1,888 | -482 | -26 |
Merck & Co. Inc. | Cozaar/Hyzaar | Losartan and Hydrochlorothiazide | Cardiovascular Diseases | USD | Millions | 484 | 511 | 484 | 511 | -27 | -5 |
Merck & Co. Inc. | Arcoxia | Etoricoxib | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 363 | 450 | 363 | 450 | -87 | -19 |
Merck & Co. Inc. | Fosamax | Alendronate | Bone and Joint Diseases | USD | Millions | 241 | 284 | 241 | 284 | -43 | -15 |
Merck & Co. Inc. | Total Other | | | USD | Millions | 1,088 | 1,245 | 1,088 | 1,245 | -157 | -13 |
Merck & Co. Inc. | Gardasil/Gardasil 9 | HPV Quadrivalent Vaccine | Oncology | USD | Millions | 2,308 | 2,173 | 2,308 | 2,173 | 135 | 6 |
Merck & Co. Inc. | ProQuad, M-M-R II and Varivax | Measles, Mumps, Rubella and Varicella Virus Vaccine Live | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 1,676 | 1,640 | 1,676 | 1,640 | 36 | 2 |
Merck & Co. Inc. | Zostavax | Zoster Vaccine Live | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 668 | 685 | 668 | 685 | -17 | -2 |
Merck & Co. Inc. | RotaTeq | Rotavirus Vaccine | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 686 | 652 | 686 | 652 | 34 | 5 |
Merck & Co. Inc. | Pneumovax 23 | Pneumococcal Vaccine Polyvalent | Infectious Diseases (HIV, Hepatitis etc.) | USD | Millions | 821 | 641 | 821 | 641 | 180 | 28 |
Merck & Co. Inc. | Total Vaccines | | | USD | Millions | 6,159 | 5,791 | 6,159 | 5,791 | 368 | 6 |
Merck & Co. Inc. | Other Pharmaceutical | | | USD | Millions | 4,295 | 4,574 | 4,295 | 4,574 | -279 | -6 |
Merck & Co. Inc. | Total Pharmaceuticals | | | USD | Millions | 35,390 | 35,150 | 35,390 | 35,150 | 240 | 1 |
Merck & Co. Inc. | Other Segment Sales | | | USD | Millions | 4,272 | 3,862 | 4,272 | 3,862 | 410 | 11 |
Merck & Co. Inc. | Total Segment Sales | | | USD | Millions | 39,662 | 39,013 | 39,662 | 39,013 | 649 | 2 |
Merck & Co. Inc. | Other Revenues | | | USD | Millions | 460 | 794 | 460 | 794 | -334 | -42 |
Merck & Co. Inc. | Total Sales | | | USD | Millions | 40,122 | 39,807 | 40,122 | 39,807 | 315 | 1 |
Mitsubishi Tanabe | Domestic Ethical Drugs | | | YEN | Millions | 320,400 | 310,600 | 3,076 | 2,982 | 94 | 3 |
Mitsubishi Tanabe | Remicade | Infliximab | Autoimmune Disorders | YEN | Millions | 65,800 | 67,400 | 632 | 647 | -15 | -2 |
Mitsubishi Tanabe | Simponi | Golimumab | Rheumatoid Arthritis | YEN | Millions | 30,200 | 22,200 | 290 | 213 | 77 | 36 |
Mitsubishi Tanabe | Tenelia | Teneligliptin | Diabetes | YEN | Millions | 18,500 | 16,400 | 178 | 157 | 20 | 13 |
Mitsubishi Tanabe | Talion | Bepotastine | Anti-allergic | YEN | Millions | 18,900 | 18,400 | 181 | 177 | 5 | 3 |
Mitsubishi Tanabe | Lexapro | Escitalopram Oxalate | Neurological/Mental Disorders | YEN | Millions | 12,400 | 10,700 | 119 | 103 | 16 | 16 |
Mitsubishi Tanabe | Ceredist | Taltirelin | Hormonal Disorders | YEN | Millions | 11,200 | 12,500 | 108 | 120 | -12 | -10 |
Mitsubishi Tanabe | Maintate | Bisoprolol | Cardiovascular Diseases | YEN | Millions | 11,000 | 12,100 | 106 | 116 | -11 | -9 |
Mitsubishi Tanabe | Kremezin | Spherical Carbon Adsorbent | Renal Disorders | YEN | Millions | 6,600 | 7,800 | 63 | 75 | -12 | -15 |
Mitsubishi Tanabe | Depas | Etizolam | Neurological/Mental Disorders | YEN | Millions | 1,200 | 6,200 | 12 | 60 | -48 | -81 |
Mitsubishi Tanabe | Radicut | Edaravone | Neurological/Mental Disorders | YEN | Millions | 5,600 | 6,200 | 54 | 60 | -6 | -10 |
Mitsubishi Tanabe | Canaglu | Canagliflozin | Diabetes | YEN | Millions | 5,200 | 2,500 | 50 | 24 | 26 | 108 |
Mitsubishi Tanabe | Urso | Ursodiol | Gastrointestinal Disorders | YEN | Millions | 5,400 | 6,300 | 52 | 60 | -9 | -14 |
Mitsubishi Tanabe | Imusera | Fingolimod Hydrochloride | Neurological/Mental Disorders | YEN | Millions | 4,700 | 3,800 | 45 | 36 | 9 | 24 |
Mitsubishi Tanabe | BIKEN Products [Vaccines] | | | YEN | Millions | 37,700 | 38,600 | 362 | 371 | -9 | -2 |
Mitsubishi Tanabe | Influenza Vaccine | | Anti-viral | YEN | Millions | 11,800 | 12,700 | 113 | 122 | -9 | -7 |
Mitsubishi Tanabe | Tetrabik | Diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain) | Anti-viral | YEN | Millions | 8,900 | 9,800 | 85 | 94 | -9 | -9 |
Mitsubishi Tanabe | Mearubik | | Anti-viral | YEN | Millions | 5,500 | 5,500 | 53 | 53 | 0 | 0.0 |
Mitsubishi Tanabe | Varicella Vaccine | | Anti-viral | YEN | Millions | 5,200 | 5,400 | 50 | 52 | -2 | -4 |
Mitsubishi Tanabe | Tanabe Seiyaku Hanbai Products | | | YEN | Millions | 9,900 | 14,000 | 95 | 134 | -39 | -29 |
Mitsubishi Tanabe | Overseas Ethical Drugs | | | YEN | Millions | 32,200 | 21,500 | 309 | 206 | 103 | 50 |
Mitsubishi Tanabe | Radicava | Edaravone | Neurological/Mental Disorders | YEN | Millions | 6,400 | 0 | 61 | 0 | 61 | New Launch |
Mitsubishi Tanabe | Herbesser | Diltiazem | Cardiovascular Diseases | YEN | Millions | 6,300 | 6,100 | 60 | 59 | 2 | 3 |
Mitsubishi Tanabe | Novastan | Argatroban | Blood Disorders | YEN | Millions | 2,000 | 2,000 | 19 | 19 | 0 | 0.0 |
Mitsubishi Tanabe | Simponi | Golimumab | Rheumatoid Arthritis | YEN | Millions | 1,800 | 1,300 | 17 | 12 | 5 | 38 |
Mitsubishi Tanabe | Tanatril | Imidapril | Cardiovascular Diseases | YEN | Millions | 1,500 | 1,500 | 14 | 14 | 0 | 0.0 |
Mitsubishi Tanabe | Royalty Revenues, etc. | | | YEN | Millions | 81,100 | 77,500 | 779 | 744 | 35 | 5 |
Mitsubishi Tanabe | Royalty from Gilenya | Fingolimod | Neurological/Mental Disorders | YEN | Millions | 56,400 | 53,700 | 541 | 516 | 26 | 5 |
Mitsubishi Tanabe | Royalty from Invokana | Canagliflozin | Diabetes | YEN | Millions | 14,600 | 19,200 | 140 | 184 | -44 | -24 |
Mitsubishi Tanabe | OTC Products | | | YEN | Millions | 3,600 | 3,500 | 35 | 34 | 1 | 3 |
Mitsubishi Tanabe | Others | | | YEN | Millions | 1,300 | 1,900 | 12 | 18 | -6 | -32 |
Mitsubishi Tanabe | Total Sales Revenues | | | YEN | Millions | 438,900 | 415,500 | 4,213 | 3,989 | 225 | 6 |
Mylan | Central Nervous System and Anesthesia | | | USD | Millions | 2,238 | 2,030 | 2,238 | 2,030 | 208 | 10 |
Mylan | Respiratory and Allergy | | | USD | Millions | 1,383 | 1,813 | 1,383 | 1,813 | -431 | -24 |
Mylan | Infectious Disease | | | USD | Millions | 1,463 | 1,303 | 1,463 | 1,303 | 160 | 12 |
Mylan | Cardiovascular | | | USD | Millions | 1,220 | 1,165 | 1,220 | 1,165 | 54 | 5 |
Mylan | Gastroenterology | | | USD | Millions | 1,115 | 1,029 | 1,115 | 1,029 | 85 | 8 |
Mylan | Diabetes and Metabolism | | | USD | Millions | 947 | 972 | 947 | 972 | -25 | -3 |
Mylan | Oncology | | | USD | Millions | 701 | 764 | 701 | 764 | -64 | -8 |
Mylan | Women's Healthcare | | | USD | Millions | 712 | 594 | 712 | 594 | 118 | 20 |
Mylan | Dermatology | | | USD | Millions | 911 | 370 | 911 | 370 | 542 | 147 |
Mylan | Immunology | | | USD | Millions | 145 | 133 | 145 | 133 | 12 | 9 |
Mylan | Other | | | USD | Millions | 926 | 794 | 926 | 794 | 133 | 17 |
Mylan | Net Sales | | | USD | Millions | 11,760 | 10,967 | 11,760 | 10,967 | 793 | 7 |
Mylan | Other Revenues | | | USD | Millions | 148 | 110 | 148 | 110 | 38 | 35 |
Mylan | Total Revenues | | | USD | Millions | 11,908 | 11,077 | 11,908 | 11,077 | 831 | 8 |
Novartis | Gleevec/Glivec | Imatinib | Oncology | USD | Millions | 1,943 | 3,323 | 1,943 | 3,323 | -1,380 | -42 |
Novartis | Tasigna | Nilotinib | Oncology | USD | Millions | 1,841 | 1,739 | 1,841 | 1,739 | 102 | 6 |
Novartis | Subtotal Bcr-Abl Franchise | | | USD | Millions | 3,784 | 5,062 | 3,784 | 5,062 | -1,278 | -25 |
Novartis | Sandostatin | Octreotide | Oncology | USD | Millions | 1,612 | 1,646 | 1,612 | 1,646 | -34 | -2 |
Novartis | Afinitor/Votubia | Everolimus | Oncology | USD | Millions | 1,525 | 1,516 | 1,525 | 1,516 | 9 | 1 |
Novartis | Exjade/Jadenu | Deferasirox | Oncology | USD | Millions | 1,059 | 956 | 1,059 | 956 | 103 | 11 |
Novartis | Votrient | Pazopanib | Oncology | USD | Millions | 808 | 729 | 808 | 729 | 79 | 11 |
Novartis | Tafinlar/Mekinist | Dabrafenib/Trametinib | Oncology | USD | Millions | 873 | 672 | 873 | 672 | 201 | 30 |
Novartis | Jakavi | Ruxolitinib | Oncology | USD | Millions | 777 | 581 | 777 | 581 | 196 | 34 |
Novartis | Revolade/Promacta | Eltrombopag Olamine/Eltrombopag | Oncology | USD | Millions | 867 | 635 | 867 | 635 | 232 | 37 |
Novartis | Kisqali | Ribociclib | Oncology | USD | Millions | 76 | 0 | 76 | 0 | 76 | New Launch |
Novartis | Others | | | USD | Millions | 893 | 993 | 893 | 993 | -100 | -10 |
Novartis | Total Oncology | | | USD | Millions | 12,274 | 12,790 | 12,274 | 12,790 | -516 | -4 |
Novartis | Gilenya | Fingolimod | Neurological/Mental Disorders | USD | Millions | 3,185 | 3,109 | 3,185 | 3,109 | 76 | 2 |
Novartis | Others | | | USD | Millions | 102 | 124 | 102 | 124 | -22 | -18 |
Novartis | Total Neuroscience | | | USD | Millions | 3,287 | 3,233 | 3,287 | 3,233 | 54 | 2 |
Novartis | Lucentis | Ranibizumab | Ophthalmology | USD | Millions | 1,888 | 1,835 | 1,888 | 1,835 | 53 | 3 |
Novartis | Travoprost Group | Travoprost | Ophthalmology | USD | Millions | 589 | 619 | 589 | 619 | -30 | -5 |
Novartis | Topical Olopatadine Group | Olopatadine | Ophthalmology | USD | Millions | 284 | 335 | 284 | 335 | -51 | -15 |
Novartis | Systane Group | Propylene Glycol | Ophthalmology | USD | Millions | 400 | 377 | 400 | 377 | 23 | 6 |
Novartis | Other | | | USD | Millions | 2,207 | 2,297 | 2,207 | 2,297 | -90 | -4 |
Novartis | Total Ophthalmology | | | USD | Millions | 5,368 | 5,463 | 5,368 | 5,463 | -95 | -2 |
Novartis | Neoral/Sandimmun(e) | Cyclosporine | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 488 | 515 | 488 | 515 | -27 | -5 |
Novartis | Myfortic | Mycophenolic Acid | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 378 | 383 | 378 | 383 | -5 | -1 |
Novartis | Zortress/Certican | Everolimus | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 414 | 398 | 414 | 398 | 16 | 4 |
Novartis | Cosentyx | Secukinumab | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 2,071 | 1,128 | 2,071 | 1,128 | 943 | 84 |
Novartis | Ilaris | Canakinumab | Rare Diseases | USD | Millions | 402 | 283 | 402 | 283 | 119 | 42 |
Novartis | Others | | | USD | Millions | 288 | 308 | 288 | 308 | -20 | -6 |
Novartis | Total Immunology and Dermatology | | | USD | Millions | 4,041 | 3,015 | 4,041 | 3,015 | 1,026 | 34 |
Novartis | Ultibro Breezhaler | Indacaterol and Glycopyrronium Bromide | Respiratory Disorders | USD | Millions | 411 | 363 | 411 | 363 | 48 | 13 |
Novartis | Onbrez Breezhaler/Arcapta Neohaler | Indacaterol Maleate | Respiratory Disorders | USD | Millions | 112 | 143 | 112 | 143 | -31 | -22 |
Novartis | Seebri Breezhaler | Glycopyrronium Bromide | Respiratory Disorders | USD | Millions | 151 | 149 | 151 | 149 | 2 | 1 |
Novartis | Subtotal COPD1 portfolio | | | USD | Millions | 674 | 655 | 674 | 655 | 19 | 3 |
Novartis | Xolair | Omalizumab | Respiratory Disorders | USD | Millions | 920 | 835 | 920 | 835 | 85 | 10 |
Novartis | Others | | | USD | Millions | 23 | 31 | 23 | 31 | -8 | -26 |
Novartis | Total Respiratory | | | USD | Millions | 1,617 | 1,521 | 1,617 | 1,521 | 96 | 6 |
Novartis | Entresto | Sacubitril and Valsartan | Cardiovascular Diseases | USD | Millions | 507 | 170 | 507 | 170 | 337 | 198 |
Novartis | Others | | | USD | Millions | 17 | 14 | 17 | 14 | 3 | 21 |
Novartis | Total Cardio-Metabolic | | | USD | Millions | 524 | 184 | 524 | 184 | 340 | 185 |
Novartis | Exelon/Exelon Patch | Rivastigmine | Neurological/Mental Disorders | USD | Millions | 381 | 444 | 381 | 444 | -63 | -14 |
Novartis | Galvus | Vildagliptin | Diabetes | USD | Millions | 1,233 | 1,193 | 1,233 | 1,193 | 40 | 3 |
Novartis | Diovan/Co-Diovan | Hydrochlorothiazide and Valsartan | Cardiovascular Diseases | USD | Millions | 957 | 1,073 | 957 | 1,073 | -116 | -11 |
Novartis | Exforge | Amlodipine and Valsartan | Cardiovascular Diseases | USD | Millions | 960 | 926 | 960 | 926 | 34 | 4 |
Novartis | Voltaren/Cataflam | Diclofenac | Anti-inflammatory | USD | Millions | 465 | 525 | 465 | 525 | -60 | -11 |
Novartis | Ritalin/Focalin | Dexmethylphenidate | Neurological/Mental Disorders | USD | Millions | 236 | 282 | 236 | 282 | -46 | -16 |
Novartis | Others | | | USD | Millions | 1,682 | 1,913 | 1,682 | 1,913 | -231 | -12 |
Novartis | Total Established Medicines | | | USD | Millions | 5,914 | 6,356 | 5,914 | 6,356 | -442 | -7 |
Novartis | Total PharmaceuticalnBusiness Unit | | | USD | Millions | 20,751 | 19,772 | 20,751 | 19,772 | 979 | 5 |
Novartis | Total Division Net Sales | | | USD | Millions | 33,025 | 32,562 | 33,025 | 32,562 | 463 | 1 |
Novartis | Net Sales by Alcon | | | USD | Millions | 6,024 | 5,812 | 6,024 | 5,812 | 212 | 4 |
Novartis | Net Sales by Sandoz | | | USD | Millions | 10,060 | 10,144 | 10,060 | 10,144 | -84 | -1 |
Novartis | Total Group Net Sales | | | USD | Millions | 49,109 | 48,518 | 49,109 | 48,518 | 591 | 1 |
Novo Nordisk | Tresiba | Insulin Degludec | Diabetes | DKK | Millions | 7,327 | 4,056 | 1,246 | 690 | 556 | 81 |
Novo Nordisk | New-generation Insulin | | | DKK | Millions | 8,647 | 4,459 | 1,470 | 758 | 712 | 94 |
Novo Nordisk | NovoRapid/NovoLog | Insulin Aspart | Diabetes | DKK | Millions | 20,025 | 19,945 | 3,404 | 3,391 | 14 | 0.4 |
Novo Nordisk | NovoMix/NovoLog Mix | Biphasic Insulin Aspart | Diabetes | DKK | Millions | 10,257 | 10,482 | 1,744 | 1,782 | -38 | -2 |
Novo Nordisk | Levemir | Insulin Detemir | Diabetes | DKK | Millions | 14,118 | 17,083 | 2,400 | 2,904 | -504 | -17 |
Novo Nordisk | Total Modern Insulins | | | DKK | Millions | 44,400 | 47,510 | 7,548 | 8,077 | -529 | -7 |
Novo Nordisk | Human Insulins | Insulin | Diabetes | DKK | Millions | 10,072 | 11,090 | 1,712 | 1,885 | -173 | -9 |
Novo Nordisk | Total Insulin | | | DKK | Millions | 63,119 | 63,059 | 10,730 | 10,720 | 10 | 0.1 |
Novo Nordisk | Victoza | Liraglutide | Diabetes | DKK | Millions | 23,173 | 20,046 | 3,939 | 3,408 | 532 | 16 |
Novo Nordisk | Other Diabetes Care | | | DKK | Millions | 4,023 | 4,267 | 684 | 725 | -41 | -6 |
Novo Nordisk | of which Saxenda | Liraglutide | Weight Loss and Obesity | DKK | Millions | 2,562 | 1,577 | 436 | 268 | 167 | 62 |
Novo Nordisk | Total Diabetes Care | | | DKK | Millions | 92,877 | 88,949 | 15,789 | 15,121 | 668 | 4 |
Novo Nordisk | Haemophilia | Recombinant Human Coagulation Factor VIIa | Blood Disorders | DKK | Millions | 10,469 | 10,472 | 1,780 | 1,780 | -1 | 0.0 |
Novo Nordisk | Growth Disorders | | | DKK | Millions | 6,655 | 8,770 | 1,131 | 1,491 | -360 | -24 |
Novo Nordisk | Other Biopharmaceuticals | | | DKK | Millions | 1,695 | 3,589 | 288 | 610 | -322 | -53 |
Novo Nordisk | Total Biopharmaceuticals | | | DKK | Millions | 18,819 | 22,831 | 3,199 | 3,881 | -682 | -18 |
Novo Nordisk | Total Sales | | | DKK | Millions | 111,696 | 111,780 | 18,988 | 19,003 | -14 | -0.1 |
Ono Pharmaceuticals | Opdivo | Nivolumab | Oncology | YEN | Millions | 90,300 | 98,100 | 867 | 942 | -75 | -8 |
Ono Pharmaceuticals | Emend/Proemend | Aprepitant | Oncology | YEN | Millions | 10,100 | 9,800 | 97 | 94 | 3 | 3 |
Ono Pharmaceuticals | Glactiv | Sitagliptin Phosphate Hydrate | Diabetes | YEN | Millions | 29,000 | 28,800 | 278 | 276 | 2 | 1 |
Ono Pharmaceuticals | Forxiga | Dapagliflozin | Diabetes | YEN | Millions | 10,500 | 7,100 | 101 | 68 | 33 | 48 |
Ono Pharmaceuticals | Kinedak | Epalrestat | Diabetes | YEN | Millions | 2,400 | 3,100 | 23 | 30 | -7 | -23 |
Ono Pharmaceuticals | Recalbon | Minodronic Acid | Bone and Joint Diseases | YEN | Millions | 11,100 | 11,200 | 107 | 108 | -1 | -1 |
Ono Pharmaceuticals | Orencia SC | Abatacept | Rheumatoid Arthritis | YEN | Millions | 13,800 | 10,700 | 132 | 103 | 30 | 29 |
Ono Pharmaceuticals | Rivastach | Rivastigmine | Neurological/Mental Disorders | YEN | Millions | 9,100 | 8,500 | 87 | 82 | 6 | 7 |
Ono Pharmaceuticals | Staybla | Imidafenacin | Renal Disorders | YEN | Millions | 4,400 | 4,900 | 42 | 47 | -5 | -10 |
Ono Pharmaceuticals | Opalmon | Limaprost Alfadex | Cardiovascular Diseases | YEN | Millions | 15,200 | 18,000 | 146 | 173 | -27 | -16 |
Ono Pharmaceuticals | Onon | Pranlukast | Respiratory Disorders | YEN | Millions | 9,500 | 11,700 | 91 | 112 | -21 | -19 |
Ono Pharmaceuticals | Onoact | Landiolol | Cardiovascular Diseases | YEN | Millions | 5,900 | 5,500 | 57 | 53 | 4 | 7 |
Ono Pharmaceuticals | Foipan | Camostat Mesilate | Gastrointestinal Disorders | YEN | Millions | 3,200 | 4,000 | 31 | 38 | -8 | -20 |
Ono Pharmaceuticals | Parsabiv | Etelcalcetide | Hormonal Disorders | YEN | Millions | 4,500 | 0 | 43 | Not Available | 43 | Not Available |
Ono Pharmaceuticals | Kyprolis | Carfilzomib | Oncology | YEN | Millions | 5,400 | New Launch | 52 | Not Available | 52 | Not Available |
Ono Pharmaceuticals | Elaspol | Sivelestat | Respiratory Disorders | YEN | Millions | 0 | 300 | 0 | 3 | -3 | -100 |
Ono Pharmaceuticals | Others | | | YEN | Millions | 32,200 | 15,300 | 309 | 147 | 162 | 110 |
Ono Pharmaceuticals | Total Revenues | | | YEN | Millions | 256,600 | 237,000 | 2,463 | 2,275 | 188 | 8 |
Otsuka | Abilify | Aripiprazole | Neurological/Mental Disorders | YEN | Millions | 67,300 | 95,400 | 646 | 916 | -270 | -29 |
Otsuka | Abilify Maintena | Aripiprazole | Neurological/Mental Disorders | YEN | Millions | 70,900 | 57,200 | 681 | 549 | 132 | 24 |
Otsuka | Rexulti | Brexpiprazole | Neurological/Mental Disorders | YEN | Millions | 47,300 | 29,800 | 454 | 286 | 168 | 59 |
Otsuka | Nuedexta | Dextromethorphan and Quinidine | Neurological/Mental Disorders | YEN | Millions | 25,600 | 23,600 | 246 | 227 | 19 | 8 |
Otsuka | Pletaal/Pletal | Cilostazol | Cardiovascular Diseases | YEN | Millions | 20,900 | 23,600 | 201 | 227 | -26 | -11 |
Otsuka | Mucosta | Rebamipide | Gastrointestinal Disorders | YEN | Millions | 11,400 | 12,500 | 109 | 120 | -11 | -9 |
Otsuka | TS-1 | Tegafur, Gimeracil, Oteracil Potassium | Oncology | YEN | Millions | 20,600 | 26,900 | 198 | 258 | -60 | -23 |
Otsuka | UFT | Tegafur Uracil | Oncology | YEN | Millions | 5,700 | 6,500 | 55 | 62 | -8 | -12 |
Otsuka | Lonsurf | Trifluridine and Tipiracil | Oncology | YEN | Millions | 32,600 | 30,100 | 313 | 289 | 24 | 8 |
Otsuka | Bilanoa | Bilastine | Anti-allergic | YEN | Millions | 2,000 | 2,200 | 19 | 21 | -2 | -9 |
Otsuka | Aloxi | Palonosetron | Oncology | YEN | Millions | 14,500 | 14,000 | 139 | 134 | 5 | 4 |
Otsuka | Abraxane | Paclitaxel Protein Bound | Oncology | YEN | Millions | 21,800 | 20,700 | 209 | 199 | 11 | 5 |
Otsuka | E Keppra | Levetiracetam | Neurological/Mental Disorders | YEN | Millions | 33,800 | 28,500 | 324 | 274 | 51 | 19 |
Otsuka | Samsca/Jinarc | Tolvaptan | Cardiovascular Diseases | YEN | Millions | 64,200 | 48,900 | 616 | 469 | 147 | 31 |
Otsuka | Mucosta Ophthalmic Suspension | Rebamipide | Ophthalmology | YEN | Millions | 5,100 | 4,800 | 49 | 46 | 3 | 6 |
Otsuka | Neupro Patch | Rotigotine | Neurological/Mental Disorders | YEN | Millions | 12,100 | 10,700 | 116 | 103 | 13 | 13 |
Otsuka | Sprycel | Dasatinib | Oncology | YEN | Millions | 30,800 | 29,300 | 296 | 281 | 14 | 5 |
Otsuka | Zosyn/Tazocin | Piperacillin and Tazobactam | Anti-bacterial | YEN | Millions | 6,300 | 8,800 | 60 | 84 | -24 | -28 |
Otsuka | Diagnostics | | | YEN | Millions | 12,800 | 13,700 | 123 | 132 | -9 | -7 |
Otsuka | Parentral Nutrition | | | YEN | Millions | 111,200 | 107,400 | 1,068 | 1,031 | 36 | 4 |
Otsuka | Pharmaceutical Business Total (Excluding Export) | | | YEN | Millions | 401,800 | 387,900 | 3,857 | 3,724 | 133 | 4 |
Otsuka | Total Pharmaceuticals | | | YEN | Millions | 774,800 | 753,005 | 7,438 | 7,229 | 209 | 3 |
Otsuka | Total Nutraceuticals | | | YEN | Millions | 326,200 | 311,550 | 3,132 | 2,991 | 141 | 5 |
Otsuka | Total Consumer Products | | | YEN | Millions | 35,600 | 35,468 | 342 | 340 | 1 | 0.4 |
Otsuka | Others | | | YEN | Millions | 151,100 | 141,251 | 1,451 | 1,356 | 95 | 7 |
Otsuka | Total | | | YEN | Millions | 1,287,700 | 1,241,274 | 12,362 | 11,916 | 446 | 4 |
Otsuka | Corporate/Eliminations | | | YEN | Millions | -47,800 | -45,727 | -459 | -439 | -20 | 5 |
Otsuka | Total Consolidated | | | YEN | Millions | 1,240,000 | 1,195,547 | 11,904 | 11,477 | 427 | 4 |
Pfizer Inc. | Lyrica IH | Pregabalin | Neurological/Mental Disorders | USD | Millions | 4,511 | 4,165 | 4,511 | 4,165 | 346 | 8 |
Pfizer Inc. | Eliquis alliance revenues and direct sales | Apixaban | Cardiovascular Diseases | USD | Millions | 2,523 | 1,713 | 2,523 | 1,713 | 810 | 47 |
Pfizer Inc. | Chantix/Champix | Varenicline | Neurological/Mental Disorders | USD | Millions | 997 | 842 | 997 | 842 | 155 | 18 |
Pfizer Inc. | Viagra IH | Sildenafil Citrate | Sexual Health | USD | Millions | 823 | 1,182 | 823 | 1,182 | -359 | -30 |
Pfizer Inc. | BMP2 | Bone Morphogenetic Proteins | Bone and Joint Diseases | USD | Millions | 261 | 251 | 261 | 251 | 10 | 4 |
Pfizer Inc. | Toviaz | Fesoterodine Fumarate | Urology | USD | Millions | 257 | 258 | 257 | 258 | -1 | -0.4 |
Pfizer Inc. | All Other Internal Medicine | | | USD | Millions | 312 | 447 | 312 | 447 | -135 | -30 |
Pfizer Inc. | Internal Medicine | | | USD | Millions | 9,684 | 8,858 | 9,684 | 8,858 | 826 | 9 |
Pfizer Inc. | Prevnar 13/Prevenar 13 | Pneumococcal 7-Valent Conjugate | Anti-bacterial | USD | Millions | 5,601 | 5,718 | 5,601 | 5,718 | -117 | -2 |
Pfizer Inc. | FSME/IMMUN-TicoVac | Tick-Borne Encephalitis Virus | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 134 | 114 | 134 | 114 | 20 | 18 |
Pfizer Inc. | All Other Vaccines | | | USD | Millions | 266 | 239 | 266 | 239 | 27 | 11 |
Pfizer Inc. | Vaccines | | | USD | Millions | 6,001 | 6,070 | 6,001 | 6,070 | -69 | -1 |
Pfizer Inc. | Ibrance | Palbociclib | Oncology | USD | Millions | 3,126 | 2,136 | 3,126 | 2,136 | 990 | 46 |
Pfizer Inc. | Sutent | Sunitinib Malate | Oncology | USD | Millions | 1,081 | 1,096 | 1,081 | 1,096 | -15 | -1 |
Pfizer Inc. | Xalkori | Crizotinib | Oncology | USD | Millions | 594 | 560 | 594 | 560 | 34 | 6 |
Pfizer Inc. | Xtandi Alliance Revenues | Enzalutamide | Oncology | USD | Millions | 590 | 140 | 590 | 140 | 450 | 321 |
Pfizer Inc. | Inlyta | Axitinib | Oncology | USD | Millions | 339 | 401 | 339 | 401 | -62 | -15 |
Pfizer Inc. | Bosulif | Bosutinib | Oncology | USD | Millions | 233 | 167 | 233 | 167 | 66 | 40 |
Pfizer Inc. | All Other Oncology | | | USD | Millions | 93 | 64 | 93 | 64 | 29 | 45 |
Pfizer Inc. | Oncology | | | USD | Millions | 6,056 | 4,563 | 6,056 | 4,563 | 1,493 | 33 |
Pfizer Inc. | Enbrel (Outside the U.S. and Canada) | Etanercept | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 2,452 | 2,910 | 2,452 | 2,910 | -458 | -16 |
Pfizer Inc. | Xeljanz | Tofacitinib Citrate | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 1,345 | 927 | 1,345 | 927 | 418 | 45 |
Pfizer Inc. | Eucrisa | Crisaborole | Dermatology | USD | Millions | 67 | 0 | 67 | 0 | 67 | New Launch |
Pfizer Inc. | All other I&I | | | USD | Millions | 103 | 93 | 103 | 93 | 10 | 11 |
Pfizer Inc. | Inflammation & Immunology | | | USD | Millions | 3,968 | 3,928 | 3,968 | 3,928 | 40 | 1 |
Pfizer Inc. | BeneFIX | Coagulation Factor IX | Rare Diseases | USD | Millions | 604 | 712 | 604 | 712 | -108 | -15 |
Pfizer Inc. | Refacto AF/Xyntha | Antihemophilic Factor (Recombinant) | Rare Diseases | USD | Millions | 551 | 554 | 551 | 554 | -3 | -1 |
Pfizer Inc. | Genotropin | Somatropin | Rare Diseases | USD | Millions | 532 | 579 | 532 | 579 | -47 | -8 |
Pfizer Inc. | Somavert | Pegvisomant | Hormonal Disorders | USD | Millions | 254 | 233 | 254 | 233 | 21 | 9 |
Pfizer Inc. | All Other Rare Diseases | | | USD | Millions | 300 | 292 | 300 | 292 | 8 | 3 |
Pfizer Inc. | Total Rare Diseases | | | USD | Millions | 2,240 | 2,369 | 2,240 | 2,369 | -129 | -5 |
Pfizer Inc. | Consumer Healthcare | | | USD | Millions | 3,472 | 3,407 | 3,472 | 3,407 | 65 | 2 |
Pfizer Inc. | Pfizer Innovative Health (IH) | | | USD | Millions | 31,422 | 29,197 | 31,422 | 29,197 | 2,225 | 8 |
Pfizer Inc. | Lipitor | Atorvastatin Calcium | Cardiovascular Diseases | USD | Millions | 1,915 | 1,758 | 1,915 | 1,758 | 157 | 9 |
Pfizer Inc. | Premarin family | Conjugated Estrogens | Sexual Health | USD | Millions | 977 | 1,017 | 977 | 1,017 | -40 | -4 |
Pfizer Inc. | Norvasc | Amlodipine | Cardiovascular Diseases | USD | Millions | 926 | 962 | 926 | 962 | -36 | -4 |
Pfizer Inc. | Xalatan/Xalacom | Latanoprost | Ophthalmology | USD | Millions | 335 | 362 | 335 | 362 | -27 | -7 |
Pfizer Inc. | Effexor | Venlafaxine | Neurological/Mental Disorders | USD | Millions | 297 | 277 | 297 | 277 | 20 | 7 |
Pfizer Inc. | Zoloft | Sertraline | Neurological/Mental Disorders | USD | Millions | 291 | 304 | 291 | 304 | -13 | -4 |
Pfizer Inc. | EpiPen | Epinephrine | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 290 | 386 | 290 | 386 | -96 | -25 |
Pfizer Inc. | Zithromax/Zmax | Azithromycin | Anti-bacterial | USD | Millions | 270 | 272 | 270 | 272 | -2 | -1 |
Pfizer Inc. | Relpax | Eletriptan Hydrobromide | Neurological/Mental Disorders | USD | Millions | 236 | 324 | 236 | 324 | -88 | -27 |
Pfizer Inc. | Xanax/Xanax XR | Alprazolam | Neurological/Mental Disorders | USD | Millions | 225 | 223 | 225 | 223 | 2 | 1 |
Pfizer Inc. | Sildenafil Citrate | Sildenafil Citrate | Erectile Dysfunction | USD | Millions | 56 | 0 | 56 | 0 | 56 | New Launch |
Pfizer Inc. | All Other Legacy Established Products | | | USD | Millions | 5,077 | 5,312 | 5,077 | 5,312 | -235 | -4 |
Pfizer Inc. | Legacy Established Products | | | USD | Millions | 10,894 | 11,197 | 10,894 | 11,197 | -303 | -3 |
Pfizer Inc. | Celebrex | Celecoxib | Bone and Joint Diseases | USD | Millions | 775 | 733 | 775 | 733 | 42 | 6 |
Pfizer Inc. | Lyrica EH | Pregabalin | Neurological/Mental Disorders | USD | Millions | 553 | 801 | 553 | 801 | -248 | -31 |
Pfizer Inc. | Vfend | Voriconazole | Anti-fungal | USD | Millions | 421 | 590 | 421 | 590 | -169 | -29 |
Pfizer Inc. | Viagra EH | Sildenafil Citrate | Sexual Health | USD | Millions | 382 | 383 | 382 | 383 | -1 | -0.3 |
Pfizer Inc. | Pristiq | Desvenlafaxine | Neurological/Mental Disorders | USD | Millions | 303 | 732 | 303 | 732 | -429 | -59 |
Pfizer Inc. | Zyvox | Linezolid | Anti-bacterial | USD | Millions | 281 | 421 | 281 | 421 | -140 | -33 |
Pfizer Inc. | Revatio | Sildenafil | Cardiovascular Diseases | USD | Millions | 252 | 285 | 252 | 285 | -33 | -12 |
Pfizer Inc. | All other Peri-LOE Products | | | USD | Millions | 257 | 275 | 257 | 275 | -18 | -7 |
Pfizer Inc. | Peri-LOE Products | | | USD | Millions | 3,223 | 4,220 | 3,223 | 4,220 | -997 | -24 |
Pfizer Inc. | Medrol | Methylprednisolone | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 483 | 450 | 483 | 450 | 33 | 7 |
Pfizer Inc. | Sulperazon | Cefoperazone and Sulbactam | Urology | USD | Millions | 471 | 396 | 471 | 396 | 75 | 19 |
Pfizer Inc. | Fragmin | Dalteparin | Blood Disorders | USD | Millions | 306 | 318 | 306 | 318 | -12 | -4 |
Pfizer Inc. | Tygacil | Tigecycline | Anti-bacterial | USD | Millions | 260 | 274 | 260 | 274 | -14 | -5 |
Pfizer Inc. | Precedex | Dexmedetomidine | Neurological/Mental Disorders | USD | Millions | 243 | 264 | 243 | 264 | -21 | -8 |
Pfizer Inc. | Zosyn/Tazocin | Piperacillin/Tazobactam | Anti-bacterial | USD | Millions | 194 | 145 | 194 | 145 | 49 | 34 |
Pfizer Inc. | All Other Sterile Injectable Pharmaceuticals | | | USD | Millions | 3,715 | 4,165 | 3,715 | 4,165 | -450 | -11 |
Pfizer Inc. | Sterile Injectable Pharmaceuticals | | | USD | Millions | 5,673 | 6,016 | 5,673 | 6,016 | -343 | -6 |
Pfizer Inc. | Inflectra/Remsima | Infliximab | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 419 | 192 | 419 | 192 | 227 | 118 |
Pfizer Inc. | All Other Biosimilars | | | USD | Millions | 112 | 127 | 112 | 127 | -15 | -12 |
Pfizer Inc. | Biosimilars | | | USD | Millions | 531 | 319 | 531 | 319 | 212 | 66 |
Pfizer Inc. | Pfizer CentreOne | | | USD | Millions | 706 | 719 | 706 | 719 | -13 | -2 |
Pfizer Inc. | Hospira Infusion Systems | | | USD | Millions | 97 | 1,158 | 97 | 1,158 | -1,061 | -92 |
Pfizer Inc. | Total Lyrica | Pregabalin | Neurological/Mental Disorders | USD | Millions | 5,065 | 4,967 | 5,065 | 4,967 | 98 | 2 |
Pfizer Inc. | Total Viagra | Sildenafil Citrate | Sexual Health | USD | Millions | 1,204 | 1,565 | 1,204 | 1,565 | -361 | -23 |
Pfizer Inc. | Total Alliance Revenues | | | USD | Millions | 2,927 | 1,745 | 2,927 | 1,745 | 1,182 | 68 |
Pfizer Inc. | Pfizer Essential Health (EH) | | | USD | Millions | 21,124 | 23,626 | 21,124 | 23,626 | -2,502 | -11 |
Pfizer Inc. | Total Revenues | | | USD | Millions | 52,546 | 52,824 | 52,546 | 52,824 | -278 | -1 |
Regeneron | Eylea (In United States) | Aflibercept | Ophthalmology | USD | Millions | 3,702 | 3,323 | 3,702 | 3,323 | 379 | 11 |
Regeneron | Arcalyst | Rilonacept | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 16 | 15 | 16 | 15 | 1 | 7 |
Regeneron | Net product Sales Recorded by Regeneron | | | USD | Millions | 3,718 | 3,338 | 3,718 | 3,338 | 380 | 11 |
Regeneron | EYLEA Outside of the United States | Aflibercept | Ophthalmology | USD | Millions | 2,227 | 1,872 | 2,227 | 1,872 | 355 | 19 |
Regeneron | EYLEA Global | Aflibercept | Ophthalmology | USD | Millions | 5,929 | 5,195 | 5,929 | 5,195 | 734 | 14 |
Regeneron | Praluent | Alirocumab | Cardiovascular Diseases | USD | Millions | 195 | 116 | 195 | 116 | 79 | 68 |
Regeneron | Dupixent | Dupilumab | Dermatology | USD | Millions | 256 | New Launch | 256 | New Launch | 256 | New Launch |
Regeneron | Kevzara | Sarilumab | Rheumatoid Arthritis | USD | Millions | 13 | New Launch | 13 | New Launch | 13 | New Launch |
Regeneron | Zaltrap | Aflibercept | Oncology | USD | Millions | 84 | 72 | 84 | 72 | 12 | 17 |
Regeneron | Sanofi Collaboration Revenue | | | USD | Millions | 877 | 659 | 877 | 659 | 218 | 33 |
Regeneron | Bayer Collaboration Revenue | | | USD | Millions | 938 | 744 | 938 | 744 | 194 | 26 |
Regeneron | Other Revenue | | | USD | Millions | 339 | 119 | 339 | 119 | 220 | 185 |
Regeneron | Total Revenues | | | USD | Millions | 5,872 | 4,860 | 5,872 | 4,860 | 1,012 | 21 |
Roche | Avastin | Bevacizumab | Oncology | CHF | Millions | 6,688 | 6,783 | 7,089 | 7,190 | -101 | -1 |
Roche | Herceptin | Trastuzumab | Oncology | CHF | Millions | 7,014 | 6,782 | 7,435 | 7,189 | 246 | 3 |
Roche | MabThera/Rituxan | Rituximab | Oncology | CHF | Millions | 5,832 | 5,823 | 6,182 | 6,172 | 10 | 0.2 |
Roche | Tarceva | Erlotinib | Oncology | CHF | Millions | 843 | 1,024 | 894 | 1,085 | -192 | -18 |
Roche | Perjeta | Pertuzumab | Oncology | CHF | Millions | 2,196 | 1,846 | 2,328 | 1,957 | 371 | 19 |
Roche | Tecentriq | Atezolizumab | Oncology | CHF | Millions | 487 | 157 | 516 | 166 | 350 | 210 |
Roche | Xeloda | Capecitabine | Oncology | CHF | Millions | 453 | 506 | 480 | 536 | -56 | -10 |
Roche | Kadcyla | Trastuzumab Emtansine | Oncology | CHF | Millions | 914 | 831 | 969 | 881 | 88 | 10 |
Roche | Alecensa | Alectinib | Oncology | CHF | Millions | 362 | 182 | 384 | 193 | 191 | 99 |
Roche | Gazyva/Gazyvaro | Obinutuzumab | Oncology | CHF | Millions | 278 | 196 | 295 | 208 | 87 | 42 |
Roche | Others | | | CHF | Millions | 676 | 711 | 717 | 754 | -37 | -5 |
Roche | Total Oncology | | | CHF | Millions | 25,743 | 24,841 | 27,288 | 26,331 | 956 | 4 |
Roche | MabThera/Rituxan | Rituximab | Oncology | CHF | Millions | 1,556 | 1,477 | 1,649 | 1,566 | 84 | 5 |
Roche | Actemra/RoActemra | Tocilizumab | Immunology (Organ Transplant, Arthritis etc.) | CHF | Millions | 1,926 | 1,697 | 2,042 | 1,799 | 243 | 13 |
Roche | Xolair | Omalizumab | Immunology (Organ Transplant, Arthritis etc.) | CHF | Millions | 1,742 | 1,498 | 1,847 | 1,588 | 259 | 16 |
Roche | CellCept | Mycophenolate Mofetil | Immunology (Organ Transplant, Arthritis etc.) | CHF | Millions | 697 | 741 | 739 | 785 | -47 | -6 |
Roche | Pulmozyme | Dornase Alfa | Rare Diseases | CHF | Millions | 730 | 685 | 774 | 726 | 48 | 7 |
Roche | Esbriet | Pirfenidone | Idiopathic Pulmonary Fibrosis | CHF | Millions | 869 | 768 | 921 | 814 | 107 | 13 |
Roche | Others | | | CHF | Millions | 91 | 104 | 96 | 110 | -14 | -13 |
Roche | Total Immunology | | | CHF | Millions | 7,611 | 6,970 | 8,068 | 7,388 | 679 | 9 |
Roche | Pegasys | Peginterferon Alfa-2a | Infectious Diseases (HIV, Hepatitis etc.) | CHF | Millions | 178 | 259 | 189 | 275 | -86 | -31 |
Roche | Tamiflu | Oseltamivir Phosphate | Infectious Diseases (HIV, Hepatitis etc.) | CHF | Millions | 535 | 794 | 567 | 842 | -275 | -33 |
Roche | Valcyte/Cymevene | Ganciclovir and Valganciclovir | Immunology (Organ Transplant, Arthritis etc.) | CHF | Millions | 235 | 306 | 249 | 324 | -75 | -23 |
Roche | Rocephin | Ceftriaxone | Neurological/Mental Disorders | CHF | Millions | 299 | 298 | 317 | 316 | 1 | 0.3 |
Roche | Others | | | CHF | Millions | 110 | 116 | 117 | 123 | -6 | -5 |
Roche | Total Infectious Diseases | | | CHF | Millions | 1,357 | 1,773 | 1,438 | 1,879 | -441 | -23 |
Roche | Lucentis | Ranibizumab | Ophthalmology | CHF | Millions | 1,414 | 1,406 | 1,499 | 1,490 | 8 | 1 |
Roche | Total Opthalmology | | | CHF | Millions | 1,414 | 1,406 | 1,499 | 1,490 | 8 | 1 |
Roche | Madopar | Levodopa and Benserazide | Neurological/Mental Disorders | CHF | Millions | 334 | 290 | 354 | 307 | 47 | 15 |
Roche | Ocrevus | Ocrelizumab | Neurological/Mental Disorders | CHF | Millions | 869 | 0 | 921 | 0 | 921 | New Launch |
Roche | Others | | | CHF | Millions | 339 | 367 | 359 | 389 | -30 | -8 |
Roche | Total Neuroscience | | | CHF | Millions | 1,542 | 657 | 1,635 | 696 | 938 | 135 |
Roche | Activase/TNKase | Alteplase/Tenecteplase | Cardiovascular Diseases | CHF | Millions | 1,219 | 1,108 | 1,292 | 1,174 | 118 | 10 |
Roche | NeoRecormon/Epogin | Epoetin Beta and Epoetin Alfa | Blood Disorders | CHF | Millions | 312 | 328 | 331 | 348 | -17 | -5 |
Roche | Mircera | Methoxy Polyethylene Glycol and Epoetin Beta | Blood Disorders | CHF | Millions | 505 | 512 | 535 | 543 | -7 | -1 |
Roche | Others | | | CHF | Millions | 1,517 | 1,508 | 1,608 | 1,598 | 10 | 1 |
Roche | Total Other Therapeutic Areas | | | CHF | Millions | 3,553 | 3,456 | 3,766 | 3,663 | 103 | 3 |
Roche | Total Sales | | | CHF | Millions | 41,220 | 39,103 | 43,693 | 41,449 | 2,244 | 5 |
Roche | Royalties and Other Operating Income | | | CHF | Millions | 2,284 | 1,944 | 2,421 | 2,061 | 360 | 17 |
Roche | Total Pharmaceutical Sales | | | CHF | Millions | 43,504 | 41,047 | 46,114 | 43,510 | 2,604 | 6 |
Roche | Diagnostic Division | | | CHF | Millions | 12,079 | 11,473 | 12,804 | 12,161 | 642 | 5 |
Roche | Royalties and Other Operating Income | | | CHF | Millions | 163 | 116 | 173 | 123 | 50 | 41 |
Roche | Total Diagnostic Sales | | | CHF | Millions | 12,242 | 11,589 | 12,977 | 12,284 | 692 | 6 |
Roche | Total Group Sales | | | CHF | Millions | 55,746 | 52,636 | 59,091 | 55,794 | 3,297 | 6 |
Sanofi | Cerezyme | Imiglucerase | Rare Diseases | EURO | Millions | 730 | 748 | 905 | 928 | -22 | -2 |
Sanofi | Cerdelga | Eliglustat | Rare Diseases | EURO | Millions | 126 | 106 | 156 | 131 | 25 | 19 |
Sanofi | Myozyme/Lumizyme | Alglucosidase Alfa | Rare Diseases | EURO | Millions | 789 | 725 | 978 | 899 | 79 | 9 |
Sanofi | Fabrazyme | Agalsidase Beta | Rare Diseases | EURO | Millions | 722 | 674 | 895 | 836 | 60 | 7 |
Sanofi | Aldurazyme | Laronidase | Rare Diseases | EURO | Millions | 207 | 201 | 257 | 249 | 7 | 3 |
Sanofi | Other Rare Diseases Products | | | EURO | Millions | 314 | 323 | 389 | 401 | -11 | -3 |
Sanofi | Total Rare Diseases | | | EURO | Millions | 2,888 | 2,777 | 3,581 | 3,443 | 138 | 4 |
Sanofi | Aubagio | Teriflunomide | Neurological/Mental Disorders | EURO | Millions | 1,567 | 1,295 | 1,943 | 1,606 | 337 | 21 |
Sanofi | Lemtrada | Alemtuzumab | Neurological/Mental Disorders | EURO | Millions | 474 | 425 | 588 | 527 | 61 | 12 |
Sanofi | Total Multiple Sclerosis | | | EURO | Millions | 2,041 | 1,720 | 2,531 | 2,133 | 398 | 19 |
Sanofi | Jevtana | Cabazitaxel | Oncology | EURO | Millions | 386 | 358 | 479 | 444 | 35 | 8 |
Sanofi | Thymoglobulin | Anti-thymocyte Globulin | Immunology (Organ Transplant, Arthritis etc.) | EURO | Millions | 291 | 281 | 361 | 348 | 12 | 4 |
Sanofi | Taxotere | Docetaxel | Oncology | EURO | Millions | 173 | 179 | 215 | 222 | -7 | -3 |
Sanofi | Eloxatine | Oxaliplatin | Oncology | EURO | Millions | 179 | 170 | 222 | 211 | 11 | 5 |
Sanofi | Mozobil | Plerixafor | Oncology | EURO | Millions | 163 | 152 | 202 | 188 | 14 | 7 |
Sanofi | Zaltrap | Aflibercept | Oncology | EURO | Millions | 75 | 65 | 93 | 81 | 12 | 15 |
Sanofi | Other Oncology | | | EURO | Millions | 252 | 248 | 312 | 308 | 5 | 2 |
Sanofi | Total Oncology | | | EURO | Millions | 1,519 | 1,453 | 1,884 | 1,802 | 82 | 5 |
Sanofi | Dupixent | Dupilumab | Dermatology | EURO | Millions | 219 | 0 | 272 | 0 | 272 | New Launch |
Sanofi | Kevzara | Sarilumab | Rheumatoid Arthritis | EURO | Millions | 11 | 0 | 14 | 0 | 14 | New Launch |
Sanofi | Total Immunology | | | EURO | Millions | 230 | 0 | 285 | 0 | 285 | 100 |
Sanofi | Sanofi Genzyme (Speciality Care) | | | EURO | Millions | 6,678 | 5,950 | 8,281 | 7,378 | 903 | 12 |
Sanofi | Lantus | Insulin Glargine | Diabetes | EURO | Millions | 4,622 | 5,714 | 5,731 | 7,085 | -1,354 | -19 |
Sanofi | Toujeo | Insulin Glargine | Diabetes | EURO | Millions | 816 | 649 | 1,012 | 805 | 207 | 26 |
Sanofi | Apidra | Insulin Glulisine | Diabetes | EURO | Millions | 377 | 367 | 467 | 455 | 12 | 3 |
Sanofi | Amaryl | Glimepiride | Diabetes | EURO | Millions | 337 | 362 | 418 | 449 | -31 | -7 |
Sanofi | Insuman | Insulin | Diabetes | EURO | Millions | 107 | 129 | 133 | 160 | -27 | -17 |
Sanofi | Lyxumia | Lixisenatide | Diabetes | EURO | Millions | 26 | 33 | 32 | 41 | -9 | -21 |
Sanofi | Soliqua | Insulin Glargine and Lixisenatide | Diabetes | EURO | Millions | 26 | 0 | 32 | 0 | 32 | New Launch |
Sanofi | Other Diabetes Products | | | EURO | Millions | 84 | 87 | 104 | 108 | -4 | -3 |
Sanofi | Total Diabetes | | | EURO | Millions | 6,395 | 7,341 | 7,930 | 9,103 | -1,173 | -13 |
Sanofi | Multaq | Dronedarone | Cardiovascular Diseases | EURO | Millions | 339 | 353 | 420 | 438 | -17 | -4 |
Sanofi | Praluent | Alirocumab | Cardiovascular Diseases | EURO | Millions | 171 | 105 | 212 | 130 | 82 | 63 |
Sanofi | Total Cardiovascular | | | EURO | Millions | 510 | 458 | 632 | 568 | 64 | 11 |
Sanofi | Total Diabetes & Cardiovascular | | | EURO | Millions | 6,905 | 7,799 | 8,562 | 9,671 | -1,109 | -11 |
Sanofi | Lovenox | Enoxaparin Sodium | Blood Disorders | EURO | Millions | 1,575 | 1,636 | 1,953 | 2,029 | -76 | -4 |
Sanofi | Plavix | Clopidogrel Bisulfate | Cardiovascular Diseases | EURO | Millions | 1,471 | 1,544 | 1,824 | 1,915 | -91 | -5 |
Sanofi | Renagel/Renvela | Sevelamer Hydrochloride and Sevelamer Carbonate | Urology | EURO | Millions | 802 | 922 | 994 | 1,143 | -149 | -13 |
Sanofi | Aprovel | Irbesartan/Irbesartan + Hydrochlorothiazide | Cardiovascular Diseases | EURO | Millions | 691 | 681 | 857 | 844 | 12 | 1 |
Sanofi | Depakine | Valproate Sodium | Neurological/Mental Disorders | EURO | Millions | 443 | 416 | 549 | 516 | 33 | 6 |
Sanofi | Synvisc/Synvisc One | Hylan G-F 20 | Bone and Joint Diseases | EURO | Millions | 387 | 408 | 480 | 506 | -26 | -5 |
Sanofi | Allegra | Fexofenadine Hydrochoride | Respiratory Disorders | EURO | Millions | 158 | 186 | 196 | 231 | -35 | -15 |
Sanofi | Myslee/Ambien/Stilnox | Zolpidem | Neurological/Mental Disorders | EURO | Millions | 259 | 304 | 321 | 377 | -56 | -15 |
Sanofi | Tritace | Ramipril | Cardiovascular Diseases | EURO | Millions | 241 | 245 | 299 | 304 | -5 | -2 |
Sanofi | Targocid | Teicoplanin | Anti-bacterial | EURO | Millions | 130 | 149 | 161 | 185 | -24 | -13 |
Sanofi | Lasix | Furosemide | Cardiovascular Diseases | EURO | Millions | 137 | 148 | 170 | 184 | -14 | -7 |
Sanofi | Other Rx Drugs | | | EURO | Millions | 3,467 | 3,672 | 4,299 | 4,553 | -254 | -6 |
Sanofi | Total Established Rx Products | | | EURO | Millions | 9,761 | 10,311 | 12,104 | 12,786 | -682 | -5 |
Sanofi | Generics | | | EURO | Millions | 1,778 | 1,854 | 2,205 | 2,299 | -94 | -4 |
Sanofi | Total Emerging Markets – Specialty/Care | | | EURO | Millions | 1,004 | 931 | 1,245 | 1,154 | 91 | 8 |
Sanofi | Total Emerging Markets –nDiabetes & Cardiovascular | | | EURO | Millions | 1,505 | 1,402 | 1,866 | 1,738 | 128 | 7 |
Sanofi | General Medicine & Emerging Market | | | EURO | Millions | 14,048 | 14,498 | 17,420 | 17,978 | -558 | -3 |
Sanofi | Total Pharmaceuticals | | | EURO | Millions | 25,122 | 25,914 | 31,151 | 32,133 | -982 | -3 |
Sanofi | Consumer Healthcare | | | EURO | Millions | 4,832 | 3,330 | 5,992 | 4,129 | 1,862 | 45 |
Sanofi | Polio/Pertussis/Hib | | | EURO | Millions | 1,827 | 1,495 | 2,265 | 1,854 | 412 | 22 |
Sanofi | Influenza Vaccines | | | EURO | Millions | 1,589 | 1,521 | 1,970 | 1,886 | 84 | 4 |
Sanofi | Meningitis/Pneumonia | | | EURO | Millions | 623 | 633 | 773 | 785 | -12 | -2 |
Sanofi | Travel And Other Endemics Vaccines | | | EURO | Millions | 493 | 368 | 611 | 456 | 155 | 34 |
Sanofi | Adult Booster Vaccines | | | EURO | Millions | 474 | 417 | 588 | 517 | 71 | 14 |
Sanofi | Dengvaxia | | | EURO | Millions | 3 | 55 | 4 | 68 | -64 | -95 |
Sanofi | Other Vaccines | | | EURO | Millions | 92 | 88 | 114 | 109 | 5 | 5 |
Sanofi | Vaccines | | | EURO | Millions | 5,101 | 4,577 | 6,325 | 5,675 | 650 | 11 |
Sanofi | Total Group | | | EURO | Millions | 35,055 | 33,821 | 43,468 | 41,938 | 1,530 | 4 |
Sanofi | Companion Animals | | | EURO | Millions | 0 | 1,781 | 0 | 2,208 | -2,208 | -100 |
Sanofi | Production Animals | | | EURO | Millions | 0 | 927 | 0 | 1,149 | -1,149 | -100 |
Sanofi | Total Animal Health | | | EURO | Millions | 0 | 2,708 | 0 | 3,358 | -3,358 | -100 |
Sanofi | Total Aggregate Group Sales | | | EURO | Millions | 35,055 | 36,529 | 43,468 | 45,296 | -1,828 | -4 |
Shire | Elaprase | Idursulfase | Rare Diseases | USD | Millions | 615 | 589 | 615 | 589 | 26 | 4 |
Shire | Replagal | Agalsidase Alfa | Rare Diseases | USD | Millions | 473 | 452 | 473 | 452 | 20 | 5 |
Shire | Vpriv | Velaglucerase Alfa | Rare Diseases | USD | Millions | 349 | 346 | 349 | 346 | 3 | 1 |
Shire | Genetic Diseases | | | USD | Millions | 1,438 | 1,387 | 1,438 | 1,387 | 51 | 4 |
Shire | Vyvanse | Lisdexamfetamine Dimesylate | Neurological/Mental Disorders | USD | Millions | 2,161 | 2,014 | 2,161 | 2,014 | 147 | 7 |
Shire | Adderall XR | Amphetamine, Dextroamphetamine | Neurological/Mental Disorders | USD | Millions | 348 | 364 | 348 | 364 | -16 | -4 |
Shire | Mydayis | Mixed Salts of a Single-Entity Amphetamine | Neurological/Mental Disorders | USD | Millions | 22 | 0 | 22 | 0 | 22 | New Launch |
Shire | Other Neuroscience | | | USD | Millions | 133 | 113 | 133 | 113 | 21 | 18 |
Shire | Neuroscience | | | USD | Millions | 2,664 | 2,491 | 2,664 | 2,491 | 174 | 7 |
Shire | Hemophilia | | | USD | Millions | 2,957 | 1,789 | 2,957 | 1,789 | 1,168 | 65 |
Shire | Inhibitor Therapies | | | USD | Millions | 828 | 452 | 828 | 452 | 377 | 83 |
Shire | Hematology | | | USD | Millions | 3,786 | 2,241 | 3,786 | 2,241 | 1,545 | 69 |
Shire | Lialda/Mezavant | Mesalamine | Anti-inflammatory | USD | Millions | 569 | 792 | 569 | 792 | -223 | -28 |
Shire | Pentasa | Mesalazine | Gastrointestinal Disorders | USD | Millions | 313 | 309 | 313 | 309 | 4 | 1 |
Shire | Gattex/Revestive | Teduglutide | Gastrointestinal Disorders | USD | Millions | 336 | 219 | 336 | 219 | 116 | 53 |
Shire | Natpara | Parathyroid Hormone | Hormonal Disorders | USD | Millions | 147 | 85 | 147 | 85 | 62 | 73 |
Shire | Other Internal Medicine | | | USD | Millions | 305 | 349 | 305 | 349 | -45 | -13 |
Shire | Internal Medicine | | | USD | Millions | 1,670 | 1,756 | 1,670 | 1,756 | -85 | -5 |
Shire | Immunoglobulin Therapies | | | USD | Millions | 2,237 | 1,144 | 2,237 | 1,144 | 1,093 | 96 |
Shire | Cinryze | Complement C1 esterase | Immunology (Organ Transplant, Arthritis etc.) | USD | Millions | 699 | 680 | 699 | 680 | 19 | 3 |
Shire | Firazyr | Icatibant | Rare Diseases | USD | Millions | 663 | 579 | 663 | 579 | 85 | 15 |
Shire | Kalbitor | Ecallantide | Dermatology | USD | Millions | 67 | 52 | 67 | 52 | 15 | 29 |
Shire | Bio Therapeutics | | | USD | Millions | 704 | 372 | 704 | 372 | 332 | 89 |
Shire | Immunology | | | USD | Millions | 4,370 | 2,827 | 4,370 | 2,827 | 1,543 | 55 |
Shire | Oncology | | | USD | Millions | 262 | 131 | 262 | 131 | 131 | 101 |
Shire | Ophthalmology | | | USD | Millions | 259 | 54 | 259 | 54 | 205 | 376 |
Shire | Total Product Sales | | | USD | Millions | 14,449 | 10,886 | 14,449 | 10,886 | 3,563 | 33 |
Shire | Total Royalties and Other Revenues | | | USD | Millions | 712 | 511 | 712 | 511 | 201 | 39 |
Shire | Total Revenues | | | USD | Millions | 15,161 | 11,397 | 15,161 | 11,397 | 3,764 | 33 |
Takeda | Adcetris | Brentuximab Vedotin | Oncology | YEN | Millions | 37,200 | 28,100 | 357 | 270 | 87 | 32 |
Takeda | Amitiza | Lubiprostone | Gastrointestinal Disorders | YEN | Millions | 34,500 | 34,500 | 331 | 331 | 0 | 0.0 |
Takeda | Uloric | Febuxostat | Rheumatoid Arthritis | YEN | Millions | 46,200 | 41,900 | 444 | 402 | 41 | 10 |
Takeda | Colcrys | Colchicine | Anti-inflammatory | YEN | Millions | 41,500 | 41,800 | 398 | 401 | -3 | -1 |
Takeda | Nesina | Alogliptin | Diabetes | YEN | Millions | 52,200 | 48,700 | 501 | 468 | 34 | 7 |
Takeda | Azilva | Azilsartan | Cardiovascular Diseases | YEN | Millions | 71,800 | 65,700 | 689 | 631 | 59 | 9 |
Takeda | Dexilant | Dexlansoprazole | Gastrointestinal Disorders | YEN | Millions | 67,700 | 65,500 | 650 | 629 | 21 | 3 |
Takeda | Candesartan | Candesartan | Cardiovascular Diseases | YEN | Millions | 24,500 | 45,300 | 235 | 435 | -200 | -46 |
Takeda | Entyvio | Vedolizumab | Anti-inflammatory | YEN | Millions | 189,900 | 129,700 | 1,823 | 1,245 | 578 | 46 |
Takeda | Prevacid/Lansoprazole | Lansoprazole | Gastrointestinal Disorders | YEN | Millions | 38,600 | 53,400 | 371 | 513 | -142 | -28 |
Takeda | Pantoprazole | Pantoprazole | Gastrointestinal Disorders | YEN | Millions | 67,000 | 78,800 | 643 | 756 | -113 | -15 |
Takeda | Leuprorelin | Leuprorelin | Oncology | YEN | Millions | 114,000 | 116,700 | 1,094 | 1,120 | -26 | -2 |
Takeda | Velcade | Bortezomib | Oncology | YEN | Millions | 141,900 | 139,100 | 1,362 | 1,335 | 27 | 2 |
Takeda | Ninlaro | Ixazomib | Oncology | YEN | Millions | 43,100 | 20,800 | 414 | 200 | 214 | 107 |
Takeda | Takecab | Vonoprazan Fumarate | Gastrointestinal Disorders | YEN | Millions | 51,500 | 30,700 | 494 | 295 | 200 | 68 |
Takeda | Brintellix/Trintellix | Vortioxetine | Neurological/Mental Disorders | YEN | Millions | 46,700 | 29,200 | 448 | 280 | 168 | 60 |
Takeda | Lotriga | Omega-3-acid Ethyl Esters | Cardiovascular Diseases | YEN | Millions | 31,200 | 26,600 | 300 | 255 | 44 | 17 |
Takeda | Vectibix | Panitumumab | Oncology | YEN | Millions | 19,200 | 18,800 | 184 | 180 | 4 | 2 |
Takeda | Reminyl | Galantamine | Neurological/Mental Disorders | YEN | Millions | 17,900 | 17,200 | 172 | 165 | 7 | 4 |
Takeda | Enbrel | Etanercept | Immunology (Organ Transplant, Arthritis etc.) | YEN | Millions | 39,300 | 40,700 | 377 | 391 | -13 | -3 |
Takeda | Benet | Risedronate Sodium Hydrate | Bone and Joint Diseases | YEN | Millions | 7,700 | 8,600 | 74 | 83 | -9 | -10 |
Takeda | Rozerem | Ramelteon | Neurological/Mental Disorders | YEN | Millions | 8,800 | 7,900 | 84 | 76 | 9 | 11 |
Takeda | Alinamin | Fursultiamine | Nutritional Deficiency | YEN | Millions | 25,900 | 23,800 | 249 | 228 | 20 | 9 |
Takeda | Alinamin Health Tonic | Fursultiamine | Nutritional Deficiency | YEN | Millions | 15,100 | 15,800 | 145 | 152 | -7 | -4 |
Takeda | Biofermin | Bifidobacterium | Gastrointestinal Disorders | YEN | Millions | 6,200 | 7,200 | 60 | 69 | -10 | -14 |
Takeda | Benza | Isopropamide Iodide | Anti-cholinergic | YEN | Millions | 9,600 | 11,700 | 92 | 112 | -20 | -18 |
Takeda | Borraginol | Prednisolone Acetate, Lidocaine, Allantoin and Vitamin E | Hemorrhoids | YEN | Millions | 4,600 | 4,500 | 44 | 43 | 1 | 2 |
Takeda | Mytear | | | YEN | Millions | 2,600 | 0 | 25 | 0 | 25 | New Launch |
Takeda | Others | | | YEN | Millions | 530,000 | 698,000 | 5,088 | 6,701 | -1,613 | -24 |
Takeda | Total Revenues | | | YEN | Millions | 1,786,000 | 1,851,200 | 17,146 | 17,772 | -626 | -4 |
Teva | Copaxone | Glatiramer Acetate | Neurological/Mental Disorders | USD | Millions | 3,801 | 4,223 | 3,801 | 4,223 | -422 | -10 |
Teva | Azilect | Rasagiline | Neurological/Mental Disorders | USD | Millions | 170 | 410 | 170 | 410 | -240 | -59 |
Teva | Nuvigil | Armodafinil | Neurological/Mental Disorders | USD | Millions | 61 | 200 | 61 | 200 | -139 | -70 |
Teva | Others | | | USD | Millions | 394 | 450 | 394 | 450 | -56 | -12 |
Teva | Total Neuroscience | | | USD | Millions | 4,426 | 5,283 | 4,426 | 5,283 | -857 | -16 |
Teva | Treanda and Bendeka | Bendamustine | Oncology | USD | Millions | 658 | 661 | 658 | 661 | -3 | -0.5 |
Teva | Others | | | USD | Millions | 477 | 478 | 477 | 478 | -1 | -0.2 |
Teva | Total Oncology | | | USD | Millions | 1,135 | 1,139 | 1,135 | 1,139 | -4 | -0.4 |
Teva | ProAir | Albuterol Sulfate | Respiratory Disorders | USD | Millions | 501 | 565 | 501 | 565 | -64 | -11 |
Teva | Qvar | Beclomethasone | Respiratory Disorders | USD | Millions | 361 | 462 | 361 | 462 | -101 | -22 |
Teva | Others | | | USD | Millions | 408 | 247 | 408 | 247 | 161 | 65 |
Teva | Total Respiratory | | | USD | Millions | 1,270 | 1,274 | 1,270 | 1,274 | -4 | -0.3 |
Teva | Women's Health | | | USD | Millions | 426 | 458 | 426 | 458 | -32 | -7 |
Teva | Other Specialilty Medicines | | | USD | Millions | 657 | 520 | 657 | 520 | 137 | 26 |
Teva | Speciality Medicines | | | USD | Millions | 7,914 | 8,674 | 7,914 | 8,674 | -760 | -9 |
Teva | All Others | | | USD | Millions | 2,214 | 1,239 | 2,214 | 1,239 | 975 | 79 |
Teva | Generic Medicines | | | USD | Millions | 12,257 | 11,990 | 12,257 | 11,990 | 267 | 2 |
Teva | Total Sales | | | USD | Millions | 22,385 | 21,903 | 22,385 | 21,903 | 482 | 2 |
Valeant Pharmaceuticals | Bausch + Lomb/International | | | USD | Millions | 4,871 | 4,927 | 4,871 | 4,927 | -56 | -1 |
Valeant Pharmaceuticals | Branded Rx | | | USD | Millions | 2,475 | 2,828 | 2,475 | 2,828 | -353 | -12 |
Valeant Pharmaceuticals | Wellbutrin | Bupropion | Neurological/Mental Disorders | USD | Millions | 234 | 279 | 234 | 279 | -45 | -16 |
Valeant Pharmaceuticals | Xenazine | Tetrabenazine | Rare Diseases | USD | Millions | 113 | 157 | 113 | 157 | -44 | -28 |
Valeant Pharmaceuticals | Isuprel | Isoprenaline | Cardiovascular Diseases | USD | Millions | 105 | 178 | 105 | 178 | -73 | -41 |
Valeant Pharmaceuticals | Syprine | Trientine Hydrochloride | Genetic Disorders | USD | Millions | 91 | 88 | 91 | 88 | 3 | 3 |
Valeant Pharmaceuticals | Cuprimine | Penicillamine | Rare Diseases | USD | Millions | 78 | 104 | 78 | 104 | -26 | -25 |
Valeant Pharmaceuticals | Ativan | Lorazepam | Neurological/Mental Disorders | USD | Millions | 60 | 41 | 60 | 41 | 19 | 46 |
Valeant Pharmaceuticals | Migranal | Dihydroergotamine Mesylate | Neurological/Mental Disorders | USD | Millions | 53 | 54 | 53 | 54 | -1 | -2 |
Valeant Pharmaceuticals | Mephyton | Phytonadione | Blood Disorders | USD | Millions | 51 | 56 | 51 | 56 | -5 | -9 |
Valeant Pharmaceuticals | Glumetza | Metformin Hydrochloride | Diabetes | USD | Millions | 39 | 67 | 39 | 67 | -28 | -42 |
Valeant Pharmaceuticals | Aplenzin | Bupropion Hydrobromide | Neurological/Mental Disorders | USD | Millions | 31 | 42 | 31 | 42 | -11 | -26 |
Valeant Pharmaceuticals | Other Products Revenues | | | USD | Millions | 509 | 900 | 509 | 900 | -391 | -43 |
Valeant Pharmaceuticals | Other Revenues | | | USD | Millions | 14 | 20 | 14 | 20 | -6 | -30 |
Valeant Pharmaceuticals | Total U.S. Diversified Revenues | | | USD | Millions | 1,378 | 1,919 | 1,378 | 1,919 | -541 | -28 |
Valeant Pharmaceuticals | Total Revenues | | | USD | Millions | 8,724 | 9,674 | 8,724 | 9,674 | -950 | -10 |
Vertex | Kalydeco | Ivacaftor | Respiratory Disorders | USD | Millions | 845 | 703 | 845 | 703 | 142 | 20 |
Vertex | Orkambi | Lumacaftor/Ivacaftor | Respiratory Disorders | USD | Millions | 1,321 | 980 | 1,321 | 980 | 341 | 35 |
Vertex | Total Product Revenues | | | USD | Millions | 2,166 | 1,683 | 2,166 | 1,683 | 483 | 29 |
Vertex | Royalty Revenues | | | USD | Millions | 8 | 17 | 8 | 17 | -9 | -52 |
Vertex | Collaborative Revenues | | | USD | Millions | 316 | 2 | 316 | 2 | 314 | 16,173 |
Vertex | Total Sales | | | USD | Millions | 2,490 | 1,702 | 2,490 | 1,702 | 788 | 46 |